var title_f12_39_12912="Detailed anatomy fifth metatarsal";
var content_f12_39_12912=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Detailed anatomy fifth metatarsal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_39_12912=[""].join("\n");
var outline_f12_39_12912=null;
var title_f12_39_12913="Glomerular anatomy";
var content_f12_39_12913=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F58117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F58117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomy of the glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The bottom drawing is a diagram of part of a capillary tuft with the mesangial cells (M) in the middle surrounded by capillaries. The capillary wall has three layers composed of the fenestrated endothelial cells (En), the basement membrane, and the epithelial cells (Ep) which attach to the basement membrane by discrete foot processes. Between the foot processes are slit pores which are closed by a thin membrane, the slit diaphragm. The glomerular basement membrane surrounds the capillary loops, but most of the mesangium is separated from the capillary lumen only by the relatively permeable fenestrated endothelium (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Vander, R, Renal Physiology, 2d ed, McGraw-Hill, New York, 1980, and Latta, H, in Handbook of Physiology, sec 8, Renal Physiology, vol I, Orloff, J, Berliner, RW, Geiger, R, (Eds), American Physiological Society, Washington, DC, 1973",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_39_12913=[""].join("\n");
var outline_f12_39_12913=null;
var title_f12_39_12914="Patient information: Chronic lymphocytic leukemia (CLL) (The Basics)";
var content_f12_39_12914=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/47/2802\">",
"         Patient information: Bone marrow transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/12/13506\">",
"         Patient information: Hairy cell leukemia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/13/38098\">",
"         Patient information: Leukemia in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/4/34886\">",
"         Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/10/6309\">",
"         Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Chronic lymphocytic leukemia (CLL) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/chronic-lymphocytic-leukemia-cll-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13396889\">",
"      <span class=\"h1\">",
"       What is chronic lymphocytic leukemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Chronic lymphocytic leukemia, called &ldquo;CLL,&rdquo; is a type of blood cancer that usually grows very slowly.",
"     </p>",
"     <p>",
"      Blood is made up of different types of cells. These cells are made in the middle of your bones, in a part called the bone marrow. When people have CLL, their bone marrow makes abnormal blood cells. These abnormal blood cells grow out of control, get into the blood, and travel around the body. Sometimes, these cells collect in certain parts of the body.",
"     </p>",
"     <p>",
"      When the bone marrow makes abnormal blood cells, it does not make enough of the normal blood cells a person&rsquo;s body needs. This can cause symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13396896\">",
"      <span class=\"h1\">",
"       What are the symptoms of CLL?",
"      </span>",
"      &nbsp;&mdash;&nbsp;CLL does not usually cause symptoms when it is in the early stages, and people might not know that they have it. Many times, people are diagnosed after having routine blood tests.",
"     </p>",
"     <p>",
"      When CLL does cause symptoms, the most common ones are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Feeling very tired and weak",
"       </li>",
"       <li>",
"        Swollen lymph nodes in the neck, under the arm, or in the groin &ndash; Lymph nodes are bean-shaped organs that are part of the body&rsquo;s infection-fighting system.",
"       </li>",
"       <li>",
"        Getting sick from infections more easily than normal",
"       </li>",
"       <li>",
"        Fevers, drenching sweats at night, and losing weight without trying to",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13396903\">",
"      <span class=\"h1\">",
"       Is there a test for CLL?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will talk with you, do an exam, and do blood tests. He or she might also do a bone marrow biopsy. For this test, a doctor takes a very small sample of the bone marrow. Then another doctor will look at the cells under a microscope to see if abnormal (cancer) cells are present.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13396910\">",
"      <span class=\"h1\">",
"       How is CLL treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors can treat CLL in different ways. Sometimes, doctors do not treat CLL right away. Your doctor might not treat your CLL right away if it is slow-growing and not causing any symptoms. But your doctor will watch your CLL closely by doing exams and blood tests until treatment is needed.",
"     </p>",
"     <p>",
"      CLL is usually treated if it is causing symptoms or growing fast. Most patients with CLL are treated with chemotherapy. Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells. There are many different chemotherapy drugs that are used to treat CLL. Your doctor will work with you to choose the ones that are right for you.",
"     </p>",
"     <p>",
"      When people have chemotherapy, they can get sick from infections more easily than normal. Because of this, it&rsquo;s important to wash your hands often and stay away from people who are sick. Let your doctor or nurse know right away if you get a fever.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13396917\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, your doctor will check you every so often to see if the cancer comes back. Regular follow-ups include talking with your doctor, exams, and blood tests. Sometimes, your doctor will also do a bone marrow biopsy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13396924\">",
"      <span class=\"h1\">",
"       What happens if the CLL comes back?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the CLL comes back, your doctor will talk with you about other possible treatments. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Chemotherapy &ndash; You might get the same chemotherapy medicines that you got before, or you might get different ones.",
"       </li>",
"       <li>",
"        Bone marrow transplant &ndash; This treatment replaces cells in the bone marrow that are killed by chemotherapy or radiation. These &ldquo;donor&rdquo; cells come from another person whose blood matches yours.",
"       </li>",
"       <li>",
"        Surgery to remove an organ called the spleen",
"       </li>",
"       <li>",
"        Treatments to reduce symptoms &ndash; For example, your doctor can give you medicines to help reduce the number of infections that you get.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13396931\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to follow all your doctor&rsquo;s instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for CLL involves making many choices, such as what treatment to have and when.",
"     </p>",
"     <p>",
"      Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13396938\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/13/38098?source=see_link\">",
"       Patient information: Leukemia in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=see_link\">",
"       Patient information: Bone marrow transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/12/13506?source=see_link\">",
"       Patient information: Hairy cell leukemia (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/10/6309?source=see_link\">",
"       Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?12/39/12914?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15791 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-D7E3B57AC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_39_12914=[""].join("\n");
var outline_f12_39_12914=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13396889\">",
"      What is chronic lymphocytic leukemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13396896\">",
"      What are the symptoms of CLL?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13396903\">",
"      Is there a test for CLL?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13396910\">",
"      How is CLL treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13396917\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13396924\">",
"      What happens if the CLL comes back?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13396931\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13396938\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/10/6309?source=related_link\">",
"      Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/12/13506?source=related_link\">",
"      Patient information: Hairy cell leukemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/13/38098?source=related_link\">",
"      Patient information: Leukemia in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_39_12915="Lidocaine (ophthalmic): Patient drug information";
var content_f12_39_12915=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lidocaine (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/30/4579?source=see_link\">",
"     see \"Lidocaine (ophthalmic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/59/30642?source=see_link\">",
"     see \"Lidocaine (ophthalmic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8768586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Akten&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691299",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used during eye surgery.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702388",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lidocaine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad numbness and tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12240 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-3399DFF423-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_39_12915=[""].join("\n");
var outline_f12_39_12915=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8768586\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024245\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024244\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024249\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024250\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024252\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024247\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024254\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/30/4579?source=related_link\">",
"      Lidocaine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/59/30642?source=related_link\">",
"      Lidocaine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/54/14184?source=related_link\">",
"      Lidocaine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/58/36772?source=related_link\">",
"      Lidocaine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/11/20663?source=related_link\">",
"      Lidocaine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/3/20535?source=related_link\">",
"      Lidocaine (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/46/29413?source=related_link\">",
"      Lidocaine (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/50/33574?source=related_link\">",
"      Lidocaine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_39_12916="Botulism immune globulin (intravenous human): Drug information";
var content_f12_39_12916=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Botulism immune globulin (intravenous human): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/35/25140?source=see_link\">",
"    see \"Botulism immune globulin (intravenous human): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F142084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      BabyBIG&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F142093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Blood Product Derivative;",
"     </li>",
"     <li>",
"      Immune Globulin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F142090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/35/25140?source=see_link\">",
"      see \"Botulism immune globulin (intravenous human): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infant botulism: Infants &lt;1 year: I.V.: 75 mg/kg as a single dose as soon as diagnosis of infant botulism is made.",
"     <b>",
"      Note:",
"     </b>",
"     The recommended dose has changed multiple times since 2009; verify dose provided with  the most current available prescribing information. Reference for dose is from the October 2011 prescribing information for BabyBIG&reg;.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F142070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BabyBIG&reg;: ~ 100 mg [contains albumin (human), sucrose; supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F142058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11217339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Access to botulism immune globulin is restricted through the Infant Botulism Treatment and Prevention Program (IBTPP). Healthcare providers must contact the IBTPP on-call physician at (510) 231-7600 to review treatment indications and to obtain the medication.  For more information, refer to file://www.infantbotulism.org or contact IBTPP@infantbotulism.org.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F142072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For I.V. infusion only. Begin infusion at 25 mg/kg/hour for the first 15 minutes; if well tolerated, may increase to a maximum rate of 50 mg/kg/hour. Infuse using low volume tubing and an infusion pump with an in-line or syringe tip 18 micron filter. Infuse through a separate I.V. line (preferred). Infusion should take 97.5 minutes at the recommended rates and should be concluded within 4 hours of reconstitution (unless infusion temporarily interrupted for adverse reaction). Do not administer if solution is turbid. Infusion should be slowed or temporarily interrupted for minor side effects; discontinue in case of hypotension or anaphylaxis. Epinephrine should be available for the treatment of acute allergic reaction.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F142099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration with other medications is not recommended. If necessary, may be piggybacked into an existing I.V. line containing NS or the following dextrose solutions with or without sodium chloride: D",
"     <sub>",
"      2.5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      20",
"     </sub>",
"     W; do not dilute more than 1:2.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F142071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of infant botulism caused by toxin type A or B",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6049723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       BabyBIG&reg; may be confused with HBIG",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F142091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages reported in open-label study except where otherwise noted; may reflect pathophysiology of infant botulism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Blood pressure increased (transient, 75%), pallor (28%), edema (18%); blood pressure decreased (transient, 16%), cardiac murmur (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Irritability (41%), pyrexia (17%), body temperature decreased (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Contact dermatitis (24%), erythematous rash (22%, reported as 14% vs 8% in placebo-controlled study)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dysphagia (65%), loose stools (25%), vomiting (20%), abdominal distension (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Otitis media (11%, reported in placebo-controlled study)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Atelectasis (39%), rhonchi (34%), nasal congestion (18%), oxygen saturation decreased (17%), cough (13%), rales (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Tachycardia (7%), peripheral coldness (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration (10%), hyponatremia (6%), metabolic acidosis (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemoglobin decreased (9%), anemia (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (7%), injection site erythema (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Neurogenic bladder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Breath sounds decreased (10%), stridor (9%), lower respiratory tract infection (8%), dyspnea (6%), tachypnea (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Oral candidiasis (8%), intubation (5%), infusion rate reactions (&lt;5%, includes chills, back pain, fever, muscle cramps, nausea, vomiting, wheezing)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F142075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to human immune globulin preparations or any component of the formulation; selective immunoglobulin A deficiency",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F142061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur; immediate treatment (including epinephrine 1:1000) should be available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aseptic meningitis: Aseptic meningitis syndrome (AMS) has been reported with intravenous immune globulin administration (rare); may occur with high doses (&ge;2 g/kg).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemolysis: Immune globulin intravenous (IGIV) has been associated with antiglobulin hemolysis; monitor for signs of hemolytic anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperproteinemia: Hyperproteinemia, increased serum viscosity, and hyponatremia may occur following administration of IGIV products; distinguish hyponatremia from pseudohyponatremia to prevent volume depletion, a further increase in serum viscosity and a higher risk of thrombotic events. These adverse events have not reported with botulism immune globulin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary edema: Monitor for transfusion-related acute lung injury (TRALI); noncardiogenic pulmonary edema has been reported with IGIV use. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, and fever in the presence of normal left ventricular function. Usually occurs within 1-6 hours after infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Acute renal dysfunction (increased serum creatinine, oliguria, acute renal failure) can rarely occur; usually within 7 days of use (more likely with products stabilized with sucrose). Use with caution in the elderly, patients with renal disease, diabetes mellitus, volume depletion, sepsis, paraproteinemia, and nephrotoxic medications due to risk of renal dysfunction. In patients at risk of renal dysfunction, the rate of infusion and concentration of solution should be minimized. discontinue if renal function deteriorates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombotic events: Thrombotic events have been reported with administration of IGIV; use with caution in patients with a history of atherosclerosis or cardiovascular and/or thrombotic risk factors or patients with known/suspected hyperviscosity. Consider a baseline assessment of blood viscosity in patients at risk for hyperviscosity. Infuse at lowest practical rate in patients at risk for thrombotic events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypovolemia: Patients should not be volume depleted prior to therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adults: Not indicated for use in adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy established for infants &lt;1 year of age; not indicated for children &ge; 1 year of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: For I.V. infusion only; do not exceed recommended rate of administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F142065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Live organism vaccination should be withheld for up to 6 months following immune globulin administration.  Live vaccine given immediately prior to immune globulin may require repeat vaccination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Yellow Fever Vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F142076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Botulism immune globulin is only indicated for use in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F142067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function (BUN, serum creatinine, urinary output); vital signs (continuously during infusion); aseptic meningitis syndrome (may occur hours to days following IGIV therapy); signs of relapse (may occur up to 1 month following recovery)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F142060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     BIG-IV is purified immunoglobulin derived from the plasma of adults immunized with botulinum toxoid types A and B. BIG-IV provides antibodies to neutralize circulating toxins.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F142074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Protective neutralizing antibody levels: 6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 28 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8708 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.81.197.98-881851AA78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_39_12916=[""].join("\n");
var outline_f12_39_12916=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142084\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142093\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142090\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142070\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142058\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11217339\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142072\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142099\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142071\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6049723\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142091\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142075\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142061\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298879\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142065\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142076\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142067\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142060\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142074\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8708\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8708|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/35/25140?source=related_link\">",
"      Botulism immune globulin (intravenous human): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_39_12917="Erwinia asparaginase: Drug information";
var content_f12_39_12917=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Erwinia asparaginase: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/3/9268?source=see_link\">",
"    see \"Erwinia asparaginase: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13388919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Erwinaze&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13382001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Erwinase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13381923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Miscellaneous;",
"     </li>",
"     <li>",
"      Enzyme",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13389045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute lymphoblastic leukemia (ALL):",
"     </b>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      As a substitute for pegaspargase:",
"     </i>",
"     25,000 units/m",
"     <sup>",
"      2",
"     </sup>",
"     3 times/week (Mon, Wed, Fri) for 6 doses for each planned pegaspargase dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      As a substitute for asparaginase (E. coli):",
"     </i>",
"     25,000 units/m",
"     <sup>",
"      2",
"     </sup>",
"     for each planned asparaginase (",
"     <i>",
"      E. coli",
"     </i>",
"     ) dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      ALL induction:",
"     </b>",
"     Canadian labeling (not in the U.S. labeling): SubQ: 10,000 units/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1, 3, and 5 of week 4 and day 1 of week 5 (in combination with prednisolone, vincristine, mercaptopurine, and methotrexate)",
"     <b>",
"      or",
"     </b>",
"     10,000 units/m",
"     <sup>",
"      2",
"     </sup>",
"     3 times/week (starting week 4) for 4 weeks (in combination with prednisolone, vincristine, and daunorubicin)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13389044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute lymphoblastic leukemia (ALL):",
"     </b>",
"     I.M.: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      ALL induction:",
"     </b>",
"     <i>",
"      Canadian labeling (not in the U.S. labeling):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Children &lt;14 years: I.M.: 6000 units/m",
"     <sup>",
"      2",
"     </sup>",
"     3 times/week for 9 doses beginning day 4 of week 1 (in combination with vincristine, prednisone, methotrexate, and daunorubicin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Children &gt;14 years: SubQ: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13389049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13389048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F13389047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hemorrhagic or thrombotic event:",
"     </b>",
"     Discontinue treatment; may resume treatment upon symptom resolution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pancreatitis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild pancreatitis: Withhold treatment until signs and symptoms subside and amylase returns to normal; may resume after resolution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe or hemorrhagic pancreatitis (abdominal pain &gt;72 hours and amylase &ge;2 x ULN): Discontinue treatment; further use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Serious hypersensitivity:",
"     </b>",
"     Discontinue treatment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13388920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Erwinaze&trade;: 10,000 units [contains glucose 5 mg/vial]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13389021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F13389020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Erwinaze&trade; is distributed through Accredo Health Group, Inc. (1-877-900-9223).",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13389050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Administer I.M.; volume of each single injection site should be limited to 2 mL; use multiple injections for volumes &gt;2 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canadian labeling (additional administration routes not in the U.S. labeling): May also be administered SubQ and I.V., although I.M. and SubQ are preferred",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13381925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment (in combination with other chemotherapy) of acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to",
"     <i>",
"      E. coli",
"     </i>",
"     -derived asparaginase",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13381921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Asparaginase",
"       <i>",
"        (Erwinia)",
"       </i>",
"       may be confused with asparaginase",
"       <i>",
"        (E. coli)",
"       </i>",
"       , pegaspargase",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Erwinaze&trade; may be confused with Elaprase&reg;, Elspar&reg;, Oncaspar&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13389030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Miscellaneous: Allergic reaction/hypersensitivity (17%; grades 3/4: 5% to 9%; includes anaphylaxis, urticaria)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Thrombosis (2%; grades 3/4: &le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever (3%), headache (1%), seizure (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Glucose intolerance (2%), hyperglycemia (2%; grades 3/4: 2%), hyperammonemia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Pancreatitis (4%; grades 3/4: &le;1%), nausea (2%), vomiting (2%), abdominal pain (1%), diarrhea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Coagulation abnormalities (3%; grades 3/4: &le;1%), hemorrhage (1%; grades 3/4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Transaminases increased (3%; grades 3/4: &le;2%), hyperbilirubinemia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure, albumin decreased, alkaline phosphatase increased, anorexia, azotemia, bone marrow depression (rare), chills, cholesterol decreased, disseminated intravascular coagulation (DIC), hepatomegaly, injection site reactions, irritability, lipids (total) decreased/increased, malabsorption syndrome, proteinuria, transient ischemic event, weight loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13389026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     History of serious hypersensitivity reactions, including anaphylaxis to asparaginase (",
"     <i>",
"      Erwinia",
"     </i>",
"     ) or any component of the formulation; history of serious pancreatitis, serious thrombosis, or serious hemorrhagic event with prior asparaginase treatment",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in the U.S. labeling): Women who are or may become pregnant",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13389027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucose intolerance: In clinical trials, 2% of patients experienced glucose intolerance; may be irreversible. Monitor glucose levels (baseline and periodic) during treatment. May require insulin administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylaxis, have occurred in 5% of patients in clinical trials. Immediate treatment for hypersensitivity reactions should be available during treatment. Discontinue for serious hypersensitivity (and administer appropriate treatment for reaction).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: Pancreatitis has been reported in 4% of patients in clinical trials. Promptly evaluate with symptoms suggestive of pancreatitis. For mild pancreatitis, withhold treatment until signs and symptoms subside and amylase returns to normal; may resume after resolution. Discontinue for severe or hemorrhagic pancreatitis characterized by abdominal pain &gt;72 hours and amylase &ge;2 x ULN. Further use is contraindicated if severe pancreatitis is diagnosed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombosis and hemorrhage: Serious thrombotic events, including sagittal sinus thrombosis, have been reported with asparaginase formulations. Discontinue for thrombotic event, may resume treatment after resolution. Decreases in fibrinogen, protein C activity, protein S activity, and antithrombin III have been noted following a 2-week treatment course. Discontinue for hemorrhagic event; may resume treatment after resolution (contraindicated with history of serious thrombosis or hemorrhagic event with prior asparaginase treatment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13460902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13460900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexamethasone (Systemic): Asparaginase (Erwinia) may increase the serum concentration of Dexamethasone (Systemic). This is thought to be due to an asparaginase-related decrease in hepatic proteins responsible for dexamethasone metabolism.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13389022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13389023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. The effects on human pregnancy are unknown.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13389024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13389025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Erwinaze Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10000 unit (1): $3932.95",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13389055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, amylase, liver enzymes, blood glucose, coagulation parameters, symptoms of hypersensitivity, symptoms of pancreatitis, thrombosis, or hemorrhage",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13389037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Asparaginase catalyzes the deamidation of asparagine to aspartic acid and ammonia, reducing circulating levels of asparagine. Leukemia cells lack asparagine synthetase and are unable to synthesize asparagine. Asparaginase reduces the exogenous asparagine source for the leukemic cells, resulting in cytotoxicity specific to leukemic cells.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13389039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Half-life elimination: I.M.: ~16 hours (Asselin, 1993; Avramis, 2005)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Asselin BL, Whitin JC, Cappola DJ, et al, &ldquo;Comparative Pharmacokinetic Studies of Three Asparaginase Preparations,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1993, 11(9):1780-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/39/12917/abstract-text/8355045/pubmed\" id=\"8355045\" target=\"_blank\">",
"        8355045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Avramis VI and Panosyan EH, &ldquo;Pharmacokinetic/Pharmacodynamic Relationships of Asparaginase Formulations: The Past, the Present and Recommendations for the Future,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2005, 44(4):367-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/39/12917/abstract-text/15828851/pubmed\" id=\"15828851\" target=\"_blank\">",
"        15828851",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cheung KC, van den Bemt PM, Torringa ML, et al, &ldquo;Erroneous Exchange of Asparaginase Forms in the Treatment of Acute Lymphoblastic Leukemia,&rdquo;",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2011, 33(3):e109-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/39/12917/abstract-text/21368672/pubmed\" id=\"21368672\" target=\"_blank\">",
"        21368672",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Duval M, Suciu S, Ferster A, et al, &ldquo;Comparison of",
"      <i>",
"       Escherichia Coli",
"      </i>",
"      -Asparaginase With",
"      <i>",
"       Erwinia",
"      </i>",
"      -Asparaginase in the Treatment of Childhood Lymphoid Malignancies: Results of a Randomized European Organisation for Research and Treatment of Cancer &minus; Children's Leukemia Group Phase 3 Trial,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2002, 99(8):2734-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grace RF, Dahlberg SE, Neuberg D, et al, &ldquo;The Frequency and Management of Asparaginase-Related Thrombosis in Paediatric and Adult Patients With Acute Lymphoblastic Leukaemia Treated on Dana-Farber Cancer Institute Consortium Protocols,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2011, 152(4):452-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/39/12917/abstract-text/21210774/pubmed\" id=\"21210774\" target=\"_blank\">",
"        21210774",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salzer W, Asselin B, Supko JG, et al, &ldquo;Administration of Erwinia Asparaginase (Erwinase&reg;) Following Allergy to PEG-Asparaginase In Children and Young Adults With Acute Lymphoblastic Leukemia Treated on AALL07P2 Achieves Therapeutic Nadir Serum Asparaginase Activity: A Report From the Children's Oncology Group (COG),&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 116(21):2134 [abstract 2134 from 2010 ASH Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schrey D, Speitel K, Lanvers-Kaminsky C, et al, &ldquo;Five-Year Single-Center Study of Asparaginase Therapy Within the ALL-BFM 2000 Trial,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2011, 57(3):378-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/39/12917/abstract-text/21337682/pubmed\" id=\"21337682\" target=\"_blank\">",
"        21337682",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vrooman LM, Supko JG, Neuberg DS, et al, &ldquo;",
"      <i>",
"       Erwinia",
"      </i>",
"      Asparaginase After Allergy to",
"      <i>",
"       E. coli",
"      </i>",
"      Asparaginase in Children With Acute Lymphoblastic Leukemia,&rdquo; Pediatr Blood Cancer, 2010, 54(2):199-205.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/39/12917/abstract-text/19672973/pubmed\" id=\"19672973\" target=\"_blank\">",
"        19672973",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zalewska-Szewczyk B, Gach A, Wyka K, et al, &ldquo;The Cross-Reactivity of Anti-Asparaginase Antibodies Against Different L-Asparaginase Preparations,&rdquo;",
"      <i>",
"       Clin Exp Med",
"      </i>",
"      , 2009, 9(2):113-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/39/12917/abstract-text/19184328/pubmed\" id=\"19184328\" target=\"_blank\">",
"        19184328",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17098 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-201.211.0.116-7689716924-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_39_12917=[""].join("\n");
var outline_f12_39_12917=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13388919\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382001\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13381923\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389045\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389044\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389049\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389048\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389047\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13388920\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389021\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389020\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389050\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13381925\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13381921\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389030\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389026\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389027\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13460902\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13460900\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389022\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389023\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389024\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389025\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322923\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389055\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389037\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13389039\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17098\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17098|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/3/9268?source=related_link\">",
"      Erwinia asparaginase: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_39_12918="Alternative agents in the treatment of idiopathic membranous nephropathy";
var content_f12_39_12918=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Alternative agents in the treatment of idiopathic membranous nephropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/39/12918/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/39/12918/contributors\">",
"     Jack FM Wetzels, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/39/12918/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/39/12918/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/39/12918/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/39/12918/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/39/12918/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/39/12918/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membranous nephropathy (MN) is among the most common causes of the nephrotic syndrome in nondiabetic adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32041?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of heavy proteinuria and the nephrotic syndrome\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MN is most often idiopathic but may also be caused by a variety of drugs and underlying diseases including gold, mercury (elemental, organic, inorganic),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    , NSAIDs, systemic lupus erythematosus, malignancy, and hepatitis B and C (",
"    <a class=\"graphic graphic_table graphicRef80418 \" href=\"UTD.htm?14/6/14443\">",
"     table 1",
"    </a>",
"    ). In patients with secondary MN, cessation of the offending drug or effective treatment of the underlying disease is usually associated with improvement in the nephrotic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19306?source=see_link\">",
"     \"Causes and diagnosis of membranous nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Untreated patients with idiopathic MN have an appreciable incidence of partial or complete remission over a period of three to four years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12918/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Thus, while almost all patients with idiopathic MN should receive nonimmunosuppressive therapies (eg, angiotensin inhibition, other antihypertensive drugs to achieve the goal blood pressure, salt restriction and diuretics for control of edema and statins for hyperlipidemia), immunosuppressive therapy should be limited to patients who are at high risk for progression of disease.",
"   </p>",
"   <p>",
"    The identification of patients who are at risk for progression of disease, and the indications for the treatment of MN are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37530?source=see_link\">",
"     \"Treatment of idiopathic membranous nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary regimens used to treat idiopathic MN include a cytotoxic drug (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or, less often,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ) plus glucocorticoids or calcineurin inhibitors with or without glucocorticoids. There is also limited experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    for inducing remission in selected patients. The therapy of idiopathic MN with these agents is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37530?source=see_link\">",
"     \"Treatment of idiopathic membranous nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with idiopathic MN, a number of alternative agents have been tried. These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, synthetic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/62/2023?source=see_link\">",
"     adrenocorticotropic hormone",
"    </a>",
"    (ACTH), intravenous immune globulin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12918/abstract/3\">",
"     3",
"    </a>",
"    ]. The data evaluating the efficacy of these agents are reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MYCOPHENOLATE MOFETIL",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil (MMF) has been evaluated in the treatment of MN, both as first-line therapy and in patients who have failed prior therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     First-line therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two small randomized trials and an observational study suggested that MMF may be as effective as cytotoxic agents for first-line therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One randomized trial of 20 patients compared the effect of MMF (2.0",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      (with a starting dose of 0.8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily tapering over six months), to that of daily",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      given for three months and alternating monthly with prednisolone [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12918/abstract/4\">",
"       4",
"      </a>",
"      ]. All patients were of moderate risk with a mean protein excretion of 5.7",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      and mean baseline creatinine of 1.07",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (95",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      There was no difference between the percentages of patients who achieved complete or partial remission; (64 percent of the group that received MMF and 67 percent of the group that received chlorambucil). At the end of follow-up (only nine months after end of therapy), there were no differences in patients with treatment resistance (four versus three) or relapse (two versus one).",
"     </li>",
"     <li>",
"      In a second randomized, open label trial in 21 patients, MMF was as effective as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12918/abstract/5\">",
"       5",
"      </a>",
"      ]. Eleven patients received MMF (2.0",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      for six months) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (0.5",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      for 12 weeks); 10 patients received cyclophosphamide and glucocorticoids in an alternating monthly schedule for six months. Remission rate was similar (64 percent versus 80 percent), and there were no relapses during a follow-up of 17 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were noted in a nonrandomized study of 64 patients with membranous nephropathy and renal insufficiency (median baseline serum creatinine concentration was 1.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [159",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12918/abstract/6\">",
"     6",
"    </a>",
"    ]. Thirty-two patients were treated with MMF (1 g twice daily for 12 months) and compared to 32 historic control patients who had received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    at a dose of 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. Both groups also received glucocorticoids. The remission rate at 12 months was not significantly different (66 versus 72 percent), although treatment resistance was higher in the MMF group (five versus zero patients). During follow-up (median 23 months), the incidence of relapses was significantly higher with MMF (12 versus 4 patients).",
"   </p>",
"   <p>",
"    In contrast to the above evidence of benefit, another randomized trial of 36 patients found that MMF monotherapy was ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12918/abstract/7\">",
"     7",
"    </a>",
"    ]. All patients had normal kidney function and were of moderate risk for progression with protein excretion ranging from 5 to 10",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    All received the same conservative therapy including ACE inhibitors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ARBs, statins, low salt and low protein diet, and diuretics, and 19 patients received MMF (2",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    in addition to conservative therapy. At 12 months, there was no difference between the two groups in the frequency of complete or partial remission of proteinuria (37 versus 41 percent with conservative therapy alone) or in renal function. Adverse side effects were observed in 4 patients (20 percent) who were treated with MMF.",
"   </p>",
"   <p>",
"    It is not clear why this study did not replicate the benefit noted in the two prior randomized and the large observational study [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12918/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. One difference is that patients were treated with MMF alone rather than in combination with glucocorticoids as in the previous studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Resistant disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second issue is the efficacy of MMF in patients who have failed previous treatments with glucocorticoids, cytotoxic agents and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . Data are limited to anecdotes and small observational studies on this issue. No randomized controlled trials have been performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sixteen patients with idiopathic MN, of whom 15, 5, and 7 had failed glucocorticoids, cytotoxic agents, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , respectively, were treated with MMF for approximately eight months [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12918/abstract/8\">",
"       8",
"      </a>",
"      ]. MMF was given at 500 to 2000",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      with seven patients receiving the full dose. Concomitant glucocorticoid therapy was given to only five patients. At six months, proteinuria decreased to one-half of initial levels in six patients, with partial remissions in another two. Most patients had evidence of renal dysfunction, and with treatment there were no significant changes in the serum creatinine concentration. MMF was well-tolerated without the induction of serious side effects.",
"     </li>",
"     <li>",
"      In a retrospective report, MMF therapy was evaluated in 17 patients with MN who had one or more of the following: dependence upon glucocorticoids with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or cytotoxic agents; resistance or intolerance to glucocorticoids or cyclosporine; suboptimal response to cyclosporine; or increasing renal dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12918/abstract/9\">",
"       9",
"      </a>",
"      ]. Treatment duration and follow-up were four months to two years. Ten patients received MMF 2000",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      11 of whom also received glucocorticoids. Proteinuria significantly decreased, with the urine protein-to-creatinine ratio falling from 7.8 to 2.3 among the 15 nephrotic patients. In addition, 14 of 15 patients with either glucocorticoid or cyclosporine dependence were able to successfully withdraw from either agent. There were no significant changes in the median serum creatinine concentration, and renal function improved in three out of six patients with renal insufficiency at baseline. MMF-dependency was observed in four patients, and therapy had to be discontinued in three because of erosive gastritis, pneumonia, and squamous cell carcinoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, insufficient data support the use of MMF with glucocorticoids as initial therapy in idiopathic MN. However, MMF may be a therapeutic option for some patients with MN who have either relapsed after treatment with cytotoxic agents or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , or are unable to tolerate these regimens. There is also limited support for the use of MMF in patients who are resistant to cytotoxic agents or cyclosporine.",
"   </p>",
"   <p>",
"    Drawbacks to the use of MMF include the associated side effects, variable efficacy, and, in some [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12918/abstract/6\">",
"     6",
"    </a>",
"    ] but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12918/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], a high rate of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12918/abstract/10\">",
"     10",
"    </a>",
"    ]. The effects of MMF in patients with MN need to be studied further in larger prospective trials that have sufficient follow-up to examine renal survival outcomes.",
"   </p>",
"   <p>",
"    Based upon available data, if MMF is used, we suggest a dose of 1 g twice daily combined with glucocorticoids for 6-12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12918/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SYNTHETIC ACTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several uncontrolled reports of synthetic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/62/2023?source=see_link\">",
"     adrenocorticotropic hormone",
"    </a>",
"    (ACTH) improving proteinuria in patients with MN, although the mechanism of action remains unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12918/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. This was further examined in a randomized trial of 32 nephrotic patients with MN in whom one year of therapy with ACTH was associated with complete or partial remission in 87 percent (compared to 93 percent in the standard (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ) therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12918/abstract/14\">",
"     14",
"    </a>",
"    ]. There are no data on long-term outcomes, nor data on its use in treatment-resistant MN. Mild cushingoid effects may be observed, about equivalent to those seen with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose of 15 to 20 mg per day. Synthetic ACTH as a depot preparation is used at a starting dose of 1",
"    <span class=\"nowrap\">",
"     mg/week,",
"    </span>",
"    increasing to 1 mg twice weekly, with tapering after 6-9 months. Synthetic ACTH is not currently approved for therapeutic use in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INTRAVENOUS IMMUNE GLOBULIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous infusions of immune globulin (IVIG) have been tried with anecdotal success in a number of disorders, including lupus nephritis, granulomatosis with polyangiitis (Wegener's), and IgA nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12918/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One small, uncontrolled study suggested that this modality also may be effective in MN [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12918/abstract/16\">",
"     16",
"    </a>",
"    ], although other studies have shown little if any benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12918/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Acute renal failure after IVIG has been reported frequently, especially in formulations containing sucrose or maltose [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12918/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     AZATHIOPRINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncontrolled studies have yielded conflicting results with respect to the efficacy of combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12918/abstract/19-22\">",
"     19-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one uncontrolled study, 21 patients with progressive renal disease were treated with pulse",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      for three days),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (starting at 30",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (50 to 100",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12918/abstract/22\">",
"       22",
"      </a>",
"      ]. Treatment resulted in an initial improvement of renal function and lowering of proteinuria in all patients. In eight patients, proteinuria fell below 1",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"      During ten years of follow-up, seven patients developed ESRD. Of note, withdrawal of immunosuppressive therapy resulted in a relapse; thus, treatment was continued during follow-up.",
"     </li>",
"     <li>",
"      In another study, 13 patients with progressive renal failure were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (starting at 50 to 200",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (starting at 20 to 60",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and followed for 73 months [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12918/abstract/19\">",
"       19",
"      </a>",
"      ]. Renal function improved in 11 patients, and proteinuria decreased to less than 2",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      in 7 patients. In this study, relapses were frequent upon withdrawal of the immunosuppressive drugs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By contrast, a subsequent report suggested no benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . In an observational cohort of 50 patients with MN with nephrotic range proteinuria, there was no difference between the 33 patients treated with azathioprine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    , compared to the 17 patients who received no specific treatment, in the incidence of deteriorating renal function (42 versus 35 percent), ESRD (21 versus 18 percent) and persistent nephrotic syndrome (49 versus 42 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12918/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Of note, the groups were not well balanced, and treatment was continued for a limited time period (approximately two years). In addition, relapses remained untreated. Serious complications, such as malignancy, bacterial meningitis, and septicemia, were observed among those administered immunosuppressive therapy.",
"   </p>",
"   <p>",
"    These retrospective data suggest that, there is a limited, if any, role for combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    in the treatment of MN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Membranous nephropathy (MN) is among the most common causes of the nephrotic syndrome in nondiabetic adults. MN is most often idiopathic but may also be caused by a variety of drugs and underlying diseases. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary regimens used to treat idiopathic MN include cytotoxic drugs such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      , or calcineurin inhibitors (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ) both given with glucocorticoids. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37530?source=see_link\">",
"       \"Treatment of idiopathic membranous nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      mofetil (MMF), given with glucocorticoids, may be as effective as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      in inducing remission of proteinuria but is associated with a high rate of relapse. MMF may be a therapeutic option for some patients with MN who have either relapsed after treatment with cytotoxic agents or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , or are unable to tolerate these regimens, although there are no data on the long term effect of MMF on renal survival. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Resistant disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Synthetic ACTH has been associated with complete or partial remission in a large percentage of patients in one study. There are no data on long-term outcomes. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Synthetic ACTH'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some studies have suggested a limited benefit of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      among patients with MN. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Azathioprine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12918/abstract/1\">",
"      du Buf-Vereijken PW, Branten AJ, Wetzels JF. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy. Am J Kidney Dis 2005; 46:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12918/abstract/2\">",
"      Polanco N, Guti&eacute;rrez E, Covars&iacute; A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010; 21:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12918/abstract/3\">",
"      Kshirsagar AV, Nachman PH, Falk RJ. Alternative therapies and future intervention for treatment of membranous nephropathy. Semin Nephrol 2003; 23:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12918/abstract/4\">",
"      Chan TM, Lin AW, Tang SC, et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology (Carlton) 2007; 12:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12918/abstract/5\">",
"      Senthil Nayagam L, Ganguli A, Rathi M, et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol Dial Transplant 2008; 23:1926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12918/abstract/6\">",
"      Branten AJ, du Buf-Vereijken PW, Vervloet M, Wetzels JF. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis 2007; 50:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12918/abstract/7\">",
"      Dussol B, Morange S, Burtey S, et al. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kidney Dis 2008; 52:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12918/abstract/8\">",
"      Miller G, Zimmerman R 3rd, Radhakrishnan J, Appel G. Use of mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis 2000; 36:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12918/abstract/9\">",
"      Choi MJ, Eustace JA, Gimenez LF, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12918/abstract/10\">",
"      Appel, GB, Radhakrishnan, J, Ginzler, E. Use of mycophenolate mofetil in glomerular diseases. Transplantation 2005; 80(Suppl 2):8265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12918/abstract/11\">",
"      Berg AL, Nilsson-Ehle P, Arnadottir M. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int 1999; 56:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12918/abstract/12\">",
"      Berg AL, Arnadottir M. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrol Dial Transplant 2004; 19:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12918/abstract/13\">",
"      Picardi L, Villa G, Galli F, et al. ACTH therapy in nephrotic syndrome induced by idiopathic membranous nephropathy. Clin Nephrol 2004; 62:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12918/abstract/14\">",
"      Ponticelli C, Passerini P, Salvadori M, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 2006; 47:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12918/abstract/15\">",
"      Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney--a two-edged sword. Semin Arthritis Rheum 2004; 34:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12918/abstract/16\">",
"      Palla R, Cirami C, Panichi V, et al. Intravenous immunoglobulin therapy of membranous nephropathy: efficacy and safety. Clin Nephrol 1991; 35:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12918/abstract/17\">",
"      Yokoyama H, Goshima S, Wada T, et al. The short- and long-term outcomes of membranous nephropathy treated with intravenous immune globulin therapy. Kanazawa Study Group for Renal Diseases and Hypertension. Nephrol Dial Transplant 1999; 14:2379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12918/abstract/18\">",
"      Schifferli J, Leski M, Favre H, et al. High-dose intravenous IgG treatment and renal function. Lancet 1991; 337:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12918/abstract/19\">",
"      Brown JH, Douglas AF, Murphy BG, et al. Treatment of renal failure in idiopathic membranous nephropathy with azathioprine and prednisolone. Nephrol Dial Transplant 1998; 13:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12918/abstract/20\">",
"      Ahuja M, Goumenos D, Shortland JR, et al. Does immunosuppression with prednisolone and azathioprine alter the progression of idiopathic membranous nephropathy? Am J Kidney Dis 1999; 34:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12918/abstract/21\">",
"      Goumenos DS, Ahuja M, Davlouros P, et al. Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study. Clin Nephrol 2006; 65:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12918/abstract/22\">",
"      Bone JM, Rustom R, Williams PS. 'Progressive' versus 'indolent' idiopathic membranous glomerulonephritis. QJM 1997; 90:699.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3075 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-ADE281C057-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_39_12918=[""].join("\n");
var outline_f12_39_12918=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MYCOPHENOLATE MOFETIL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      First-line therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Resistant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SYNTHETIC ACTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INTRAVENOUS IMMUNE GLOBULIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      AZATHIOPRINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3075\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3075|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/6/14443\" title=\"table 1\">",
"      Causes membranous nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19306?source=related_link\">",
"      Causes and diagnosis of membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32041?source=related_link\">",
"      Overview of heavy proteinuria and the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37530?source=related_link\">",
"      Treatment of idiopathic membranous nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_39_12919="MRI vertebral osteomyelitis";
var content_f12_39_12919=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 632px\">",
"   <div class=\"ttl\">",
"    Three MR images of vertebral osteomyelitis due to methicillin-resistant Staphylococcus aureus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 612px; height: 648px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) T2-weighted axial image shows collections in the psoas muscles bilaterally (arrows) representing abscesses.",
"    <br/>",
"    (B) T2 -weighted sagittal image demonstrates increased signal in the L2/3 and L3/4 intervertebral disc spaces (arrows).",
"    <br/>",
"    (C) Post contrast sagittal fat saturated T1-weighted image shows enhancement in the intervertebral disc spaces (arrows) and adjacent L2 to L4 vertebral bodies (arrowheads).",
"    <div class=\"footnotes\">",
"     MRI: magnetic resonance imaging.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jenny Hoang, MBBS, Duke University Medical Center.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_39_12919=[""].join("\n");
var outline_f12_39_12919=null;
var title_f12_39_12920="Fetal ventriculomegaly";
var content_f12_39_12920=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fetal ventriculomegaly",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/39/12920/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/39/12920/contributors\">",
"     Mary E Norton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/39/12920/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/39/12920/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/39/12920/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/39/12920/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/39/12920/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/39/12920/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal ventriculomegaly is a relatively common finding on second trimester obstetrical ultrasound examination. It is clinically important because it can be caused by a variety of disorders that result in neurological, motor,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cognitive impairment. Many cases are associated with other abnormal findings, but in some fetuses, ventriculomegaly is the only abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/1\">",
"     1",
"    </a>",
"    ]. This topic will discuss the prenatal diagnosis and clinical significance of ventriculomegaly and options for management of affected pregnancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION AND NOMENCLATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The atrium of the lateral ventricle is the portion where the body, posterior horn, and temporal (inferior) horn converge. Atrial diameter remains stable between 15 and 40 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Ventriculomegaly is defined as an atrial diameter &ge;10 mm, which is 2.5 to 4 standard deviations above the mean depending on the study [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Ventriculomegaly is generally considered mild if the atrial diameter is between 10 and 15 mm and severe if &gt;15 mm, although some authors use the categories of mild (10 to 12 mm), moderate (13 to 15 mm), and severe (&ge;16 mm) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ventriculomegaly is \"isolated\" when the fetus has no other anomalies, except those that are a direct result of the ventricular enlargement. Many cases that appear isolated prenatally are ultimately found to have other abnormalities, particularly when ventriculomegaly exceeds 15 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. These abnormalities include Chiari malformations, neural tube defects, Dandy Walker malformations, agenesis of the corpus callosum, and genetic syndromes.",
"   </p>",
"   <p>",
"    Hydrocephalus is the correct term for pathologic dilatation of the brain's ventricular system from increased pressure, usually due to obstruction. Ventriculomegaly is the appropriate term when dilatation is due to other causes, such as brain dysgenesis or atrophy. Because ventricular pressure cannot be measured prenatally, the two terms are sometimes used synonymously when applied to the fetus. Most commonly, the term \"ventriculomegaly\" is used when the ventricles are mildly enlarged, and \"hydrocephalus\" is used when they measure &gt;15 mm.",
"   </p>",
"   <p>",
"    Ventriculomegaly may or may not be accompanied by macrocephaly (ie, head circumference greater than two standard deviations above the mean).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of ventriculomegaly is less than 2 percent, but reports vary widely within that range [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/9\">",
"     9",
"    </a>",
"    ]. In one study, eight cases of mild idiopathic lateral ventriculomegaly were detected among 5400 routine prenatal sonographic examinations between 16 and 22 weeks of gestation (prevalence 1 in 675 [0.15 percent]) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/10\">",
"     10",
"    </a>",
"    ]. This is a reasonable assessment of the prevalence in a general obstetrical population undergoing second trimester prenatal sonography.",
"   </p>",
"   <p>",
"    Ventriculomegaly is more common in males; the male-to-female sex ratio is 1.7 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PRENATAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Atrial assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred diagnostic technique for assessing ventriculomegaly is ultrasound measurement of the diameter of the lateral ventricles at the level of the atria. The ventricle should be measured in the axial plane, at the level of the frontal horns and cavum septi pellucidi. The calipers are positioned at the level of the internal margin of the medial and lateral walls of the atria, at the level of the glomus of the choroid plexus, on an axis perpendicular to the long axis of the lateral ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As discussed above, between 15 and 40 weeks of gestation the ventricular diameter remains stable, with reported means of 5.4 to 7.6 mm and an upper limit of normal of 10 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/2,6,10,12,13\">",
"     2,6,10,12,13",
"    </a>",
"    ]. The diagnosis of mild ventriculomegaly is made when the ventricular atria measures between 10 and 15 mm or between 10 and 12 mm, depending on the study (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68701 \" href=\"UTD.htm?24/63/25585\">",
"     image 1",
"    </a>",
"    ). Substantial interobserver variability in interpretation can occur, and is most common at borderline ventricular diameters (ie, about 10 mm) and when other central nervous system (CNS) anomalies are thought to be present [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe ventriculomegaly is diagnosed when the ventricular atria is &gt;15 mm in diameter, or &ge;16 mm if the moderate category of 13 to 15 mm is being used. Diagnosis of severe isolated ventriculomegaly implies obstruction (hydrocephalus) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78382 \" href=\"UTD.htm?41/37/42581\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Qualitative methods can also be used to assess the lateral ventricles for ventriculomegaly. Qualitatively, one looks for:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of a \"dangling choroid,\" in which the choroid plexus appears to fall toward the dependent ventricular wall [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A decrease in the ratio of choroid to cerebrospinal fluid space; the choroid plexus normally fills 50 to 100 percent of the lateral ventricle [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/17-19\">",
"       17-19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Qualitative methods are subjective and dependent upon the expertise of the sonographer or sonologist. Therefore, quantitative assessment is preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Asymmetry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some degree of asymmetry of the lateral ventricles exists in the human fetal brain, and occasionally this can be appreciated prenatally [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/20\">",
"     20",
"    </a>",
"    ]. By itself, asymmetry is not abnormal when both ventricles are of normal size. However, unilateral ventriculomegaly does occur and is occasionally diagnosed prenatally. The etiology and outcome of unilateral and bilateral ventriculomegaly are similar; therefore, counseling and management are generally the same [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/21-24\">",
"     21-24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal fetal brain is quite sonolucent and may simulate cerebrospinal fluid, which may incorrectly lead to the diagnosis of ventriculomegaly. Therefore, careful evaluation by an experienced sonologist is important in confirming the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CNS lesions that could be misdiagnosed as ventriculomegaly by an examiner inexperienced in neurosonography include holoprosencephaly, hydranencephaly, porencephaly, and various cystic lesions, such as arachnoid cysts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/44/2762?source=see_link\">",
"     \"Prenatal diagnosis of CNS anomalies other than neural tube defects and ventriculomegaly\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Large isolated choroid plexus cysts may transiently dilate the fetal cerebral ventricles. While data are available on a limited number of such cases, choroid plexus cysts are typically benign and the mild ventriculomegaly in such cases is unlikely to be clinically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/44/2762?source=see_link&amp;anchor=H10#H10\">",
"     \"Prenatal diagnosis of CNS anomalies other than neural tube defects and ventriculomegaly\", section on 'Choroid plexus cysts'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=see_link&amp;anchor=H12#H12\">",
"     \"Sonographic findings associated with fetal aneuploidy\", section on 'Choroid plexus cysts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of ventriculomegaly include idiopathic causes, chromosomal disorders and genetic syndromes, and aqueductal stenosis. In congenital aqueductal stenosis, the cerebral aqueduct is narrow or consists of several minute channels (",
"    <a class=\"graphic graphic_figure graphicRef75547 \" href=\"UTD.htm?36/40/37510\">",
"     figure 1",
"    </a>",
"    ). The narrowing may be developmental (eg, X-linked hydrocephalus with stenosis of the aqueduct of Sylvius) or due to acquired changes, such as fibrosis from infection (eg, cytomegalovirus [CMV], toxoplasmosis), intraventricular hemorrhage, or a mass. Infection can also result in isolated ventriculomegaly due to cerebral atrophy, aqueductal stenosis due to ependymal fibrosis, or communicating hydrocephalus due to inflammation of arachnoid granulations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/54/5994?source=see_link\">",
"     \"Hydrocephalus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OBSTETRICAL ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Initial work-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;After ventriculomegaly is identified, further management involves identifying whether additional abnormalities (CNS and non-CNS) are present, diagnostic evaluation for the most common causes of ventriculomegaly, and counseling patients about the prognosis and potential pregnancy interventions.",
"   </p>",
"   <p>",
"    We suggest the following approach:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Comprehensive sonographic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A physician experienced in the diagnosis of fetal anomalies should perform a comprehensive sonogram to confirm the diagnosis of ventriculomegaly and determine whether other structural abnormalities are present. Associated abnormalities have been reported in 10 to 76 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/8,27-29\">",
"     8,27-29",
"    </a>",
"    ]. Identification of these abnormalities helps in determining the cause of ventriculomegaly and the prognosis.",
"   </p>",
"   <p>",
"    A comprehensive examination requires that additional imaging of the CNS be performed, beyond that included in the basic obstetrical sonogram. Such imaging would include a detailed evaluation of the lateral, third, and fourth ventricles; corpus callosum; germinal matrix region; and cerebellum and cerebellar vermis.",
"   </p>",
"   <p>",
"    Because CNS infection can result in ventriculomegaly, it is important to look for characteristic sonographic findings of fetal infection, such as intracerebral and periventricular calcifications, hepatic calcifications, hepatosplenomegaly, ascites, and polyhydramnios. Such findings should prompt maternal serological studies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    polymerase chain reaction (PCR) analysis of amniotic fluid to aid in the diagnosis of suspected infectious etiologies (see below).",
"   </p>",
"   <p>",
"    In addition, a detailed fetal anatomic survey should be performed to look for non-CNS abnormalities since ventriculomegaly can be a component of several genetic syndromes (eg, trisomy 21). Because ventriculomegaly is a relatively non-specific finding, associated with numerous conditions, careful attention to all fetal anatomic structures, including nonspecific features of aneuploidy, is important. Although some experts suggest a fetal echocardiogram be performed routinely, we do not do this test if the heart appears normal on a detailed fetal sonogram.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Review of medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's history is reviewed for symptoms suggestive of CMV infection and exposure to sources of toxoplasmosis (eg, cats, consumption of undercooked meat) or lymphocytic choriomeningitis virus (exposure to rodents such as hamsters, mice, rats), all of which are infectious causes of ventriculomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Sporadic cases of ventriculomegaly associated with other viruses have also been reported (mumps enterovirus 71 (EV71), parainfluenza virus type 3, parvovirus B19) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/33-36\">",
"     33-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=see_link\">",
"       \"Toxoplasmosis and pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12634?source=see_link\">",
"       \"Cytomegalovirus infection in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15417?source=see_link&amp;anchor=H8#H8\">",
"       \"Aseptic meningitis in adults\", section on 'Lymphocytic choriomeningitis virus'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The family history is reviewed to identify any suggestion of L1 cell adhesion molecule (L1CAM) mutations in the family. Individuals with L1CAM mutations are characterized by neurologic abnormalities and intellectual disability and include the MASA spectrum (",
"    <strong>",
"     M",
"    </strong>",
"    ental retardation,",
"    <strong>",
"     A",
"    </strong>",
"    phasia,",
"    <strong>",
"     S",
"    </strong>",
"    huffling gait,",
"    <strong>",
"     A",
"    </strong>",
"    dducted thumbs), X-linked spastic paraplegia type 1, and X-linked agenesis of the corpus callosum. If the family history is suggestive of one of these disorders, or in male fetuses with overt isolated hydrocephalus (eg, the ventricles measure &gt;15 mm), DNA testing for a mutation in the L1 spectrum is warranted and consultation with a geneticist is recommended. We do not perform DNA testing of female fetuses or males with mild (&lt;15 mm) ventriculomegaly because the yield of such testing is likely to be low. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/54/5994?source=see_link&amp;anchor=H17#H17\">",
"     \"Hydrocephalus\", section on 'X-linked hydrocephalus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Amniocentesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;We offer amniocentesis at &ge;15 weeks for determination of the fetal karyotype, as there is an increased risk of chromosomal abnormality with even mild lateral cerebral ventriculomegaly: the reported risk of abnormal karyotype ranges from 3 to 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/8,27-29,37,38\">",
"     8,27-29,37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The amniotic fluid is also tested for alpha-fetoprotein and acetylcholinesterase to exclude an occult open neural tube defect, which can often lead to ventriculomegaly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25145?source=see_link&amp;anchor=H21#H21\">",
"     \"Prenatal screening and diagnosis of neural tube defects\", section on 'Amniocentesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Evaluation for infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCR for CMV and toxoplasmosis should also be obtained when amniocentesis is performed. If the patient declines amniocentesis, or karyotyping has been done previously, maternal serology is used to identify an infectious etiology. However, serology is neither as sensitive nor as specific as PCR on amniotic fluid, thus amniotic fluid PCR is the preferred method of evaluation for infection.",
"   </p>",
"   <p>",
"    Many cases of ventriculomegaly due to infectious causes will have other sonographic findings, such as intraabdominal or CNS calcifications. However, in some cases, the ventriculomegaly is the first (or only) sonographic feature; therefore, testing for infectious pathogens should be offered in all cases of isolated ventriculomegaly, and strongly recommended if the fetus has other features suspicious for an infectious cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal magnetic resonance imaging (MRI) can be used to identify underlying CNS abnormalities not detected by sonography. We suggest considering MRI in cases of isolated ventriculomegaly (with a normal karyotype) because cortical malformations and other potentially significant defects cannot be easily detected with ultrasound (eg, migrational abnormalities and porencephaly) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/14,39-44\">",
"     14,39-44",
"    </a>",
"    ]; however, there is no consensus on the clinical value of this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/45\">",
"     45",
"    </a>",
"    ]. The likelihood of finding another abnormality by MRI depends, in large part, on the quality of the original sonogram and varies from 5 to 50 percent in different series [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/1,15,46-49\">",
"     1,15,46-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a large series of 147 fetuses with isolated ventriculomegaly on ultrasound and normal karyotype, MRI confirmed the diagnosis in 122 (83 percent) and detected additional brain abnormalities in 25 (17 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/1\">",
"     1",
"    </a>",
"    ]. In 12 cases, the severity of ventriculomegaly was reclassified up",
"    <span class=\"nowrap\">",
"     (10/12)",
"    </span>",
"    or down",
"    <span class=\"nowrap\">",
"     (2/12).",
"    </span>",
"    Brain abnormalities were identified in",
"    <span class=\"nowrap\">",
"     5/90",
"    </span>",
"    fetuses (6 percent) with mild (10 to 12 mm) ventriculomegaly,",
"    <span class=\"nowrap\">",
"     4/29",
"    </span>",
"    fetuses (14 percent) with moderate (13 to 15 mm) ventriculomegaly, and",
"    <span class=\"nowrap\">",
"     16/28",
"    </span>",
"    fetuses (57 percent) with severe (&ge;16 mm) ventriculomegaly. The most common anomaly detected on MRI, but missed on ultrasound, was agenesis of the corpus callosum, which accounted for 11 of the 25 cases. The effects of agenesis of the corpus callosum range from subtle or mild to severe, depending on associated brain abnormalities.",
"   </p>",
"   <p>",
"    Confirmation of isolated mild ventriculomegaly increases the likelihood that long-term neurodevelopment will be normal, and identification of other CNS malformations makes it more likely that the fetus will have neurologic abnormalities, including developmental delay. However, precise data on outcomes in such cases are not yet available.",
"   </p>",
"   <p>",
"    MRI is typically done at 22 to 24 weeks of gestation because developmental milestones become more evident as gestation advances. MRI is not useful in cases of aneuploidy, when the neurologic outcome is almost certainly abnormal regardless of imaging, but may assist in determining the extent of destructive injury in fetuses with known infection, hemorrhage or ischemia, and when other sonographically evident CNS malformations, such as agenesis of the corpus callosum, are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up ultrasound examinations are obtained to look for regression or progression of ventriculomegaly, and to reevaluate for anomalies. Early isolated mild ventriculomegaly may resolve by the third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/27,29,50\">",
"     27,29,50",
"    </a>",
"    ]; progression occurs in 16 percent of cases and has been associated with a worse outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/11\">",
"     11",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H17\">",
"     'Outcome'",
"    </a>",
"    below). Follow-up ultrasounds have detected fetal abnormalities not detected on the initial scan in 13 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/11\">",
"     11",
"    </a>",
"    ]. Therefore, at least one additional detailed ultrasound examination should be performed between 28 and 34 weeks of gestation to look for CNS and non-CNS abnormalities and regression or progression of dilatation.",
"   </p>",
"   <p>",
"    Antepartum fetal testing has no proven benefit in pregnancies with isolated fetal ventriculomegaly in the absence of other findings, such as intrauterine growth restriction or oligohydramnios.",
"   </p>",
"   <p>",
"    Few data exist to support a specific management plan in those patients who continue their pregnancies. When severe ventriculomegaly is present, elective preterm delivery has been proposed so a procedure can be performed to alleviate pressure on the developing brain and avoid progressive brain damage. However, we do not suggest early delivery, given there is no evidence that it is of benefit.",
"   </p>",
"   <p>",
"    Intrauterine treatment with ventriculoamniotic shunting was performed in the 1980s. A series including 44 fetuses reported a procedure-related death rate of 10 percent, perinatal mortality rate of 17 percent, and moderate-to-severe handicaps in 66 percent of the survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/51\">",
"     51",
"    </a>",
"    ]. The expert consensus at that time was that these results did not represent an improvement in outcome over expectant management, which led to a de facto moratorium on such procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/52\">",
"     52",
"    </a>",
"    ]. Subsequently, some investigators have questioned whether improvements in prenatal diagnosis might allow better selection of those fetuses most likely to benefit from in utero shunting. At present, however, such procedures are investigational.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is wide variation in outcome of infants with prenatally diagnosed ventriculomegaly, although most children, particularly those with isolated mild (10 to 12 mm) ventriculomegaly, will have a normal outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/27-29,44,53-59\">",
"     27-29,44,53-59",
"    </a>",
"    ]. On the other hand, survival rates are more guarded and the outcome among survivors is more likely to be abnormal when ventriculomegaly is more severe or other anomalies are present.",
"   </p>",
"   <p>",
"    For example, in a series of 253 cases of ventriculomegaly, survival rates were 93 percent when the measurement was 10 to 12 mm, 84 percent with measurements &gt;12 mm, and 60 percent when other anomalies were present [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/60\">",
"     60",
"    </a>",
"    ]. Another large series (n=78) reported that in fetuses with isolated ventriculomegaly, survival rates in mild (10 to 12 mm), moderate (12 to 15 mm), and severe (&gt;15 mm) cases were 98, 80, and 33 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/27\">",
"     27",
"    </a>",
"    ]. A third series of fetuses with apparently isolated ventriculomegaly reported neonatal mortality in 3 percent with mild to moderate ventriculomegaly and in 16 percent with severe ventriculomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/8,29\">",
"     8,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, neurological, motor, and cognitive impairment are more likely when associated anomalies are present (either CNS or non-CNS), with early onset, with persistence or progression of ventriculomegaly, and with more severe ventriculomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/27,61,62\">",
"     27,61,62",
"    </a>",
"    ]. In one series [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/27\">",
"     27",
"    </a>",
"    ], normal outcome rates in mild, moderate, and severe cases that survived were 93, 75, and 63 percent, respectively. Another systematic review including 137 cases of isolated ventriculomegaly and follow-up to at least 20 months of age reported that 79 percent had normal neurodevelopment, 10 percent were mildly delayed, and 11 percent had",
"    <span class=\"nowrap\">",
"     moderate/severe",
"    </span>",
"    developmental delays [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/54\">",
"     54",
"    </a>",
"    ]. Variations in reported rates of developmental delay are related, at least in part, to the thoroughness of neurodevelopmental evaluation, length of follow-up, and inclusion or exclusion of fetuses with other anomalies.",
"   </p>",
"   <p>",
"    Prognosis has also been assessed according to progression, stability, or resolution of the ventriculomegaly. Among 106 live born infants followed in one series, ventriculomegaly increased in utero in 19, remained unchanged in 37, and improved or disappeared in 50. Normal outcomes were observed in 46 of the 50 fetuses (92 percent) in whom ventriculomegaly improved versus 13 of the 37 fetuses (35 percent) with stable ventriculomegaly and 4 of the 19 fetuses (21 percent) with worsening ventriculomegaly. Overall, in utero progression was associated with an adverse outcome in 44 percent of cases, while only 7 percent of the no-progression group had an adverse outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many neuropsychiatric disorders associated with mild enlargement of the lateral ventricles are thought to have origins in prenatal brain development. A study that compared neonatal MRI findings in 34 infants with prenatal isolated mild ventriculomegaly with 34 matched infants who had normal prenatal findings noted prenatal enlargement was associated with postnatal changes in gray and white matter maturation and development [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/63\">",
"     63",
"    </a>",
"    ]. The authors suggested that prenatal ventricle volume is an early structural marker of altered development of the cerebral cortex and may be a marker of risk for neuropsychiatric disorders. A number of case series have also suggested an association between prenatally detected mild ventriculomegaly and neuropsychiatric disorders. [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/11\">",
"     11",
"    </a>",
"    ]. At this point, there are insufficient data to confirm this association.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The range of potential outcomes should be discussed with the family. If the etiology of ventriculomegaly has been determined (eg, trisomy, CMV) or associated malformations are identified, the parents can be given more specific information than in cases where counseling is only based on ventricular width (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Outcome'",
"    </a>",
"    above). Before viability, pregnancy termination is an option and should be offered. In those patients who elect to terminate, evaluation to confirm or determine the etiology is warranted, as identifying a cause can be helpful in determining recurrence risk in future pregnancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Delivery management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventriculomegaly may or may not be accompanied by macrocephaly. Most infants with ventriculomegaly have a normal head circumference; therefore, there is no increased risk of cephalopelvic disproportion and cesarean delivery is not required except for standard obstetric complications.",
"   </p>",
"   <p>",
"    Cesarean delivery is indicated in cases in which the head circumference is increased and vaginal delivery is thought not to be possible. The cut-off for determining when a cesarean delivery is indicated will vary with gestational age at delivery, the absolute and relative head circumference (HC) and the size of the maternal pelvis. When the HC exceeds 40 cm, abdominal delivery should be considered. Pelvimetry is unlikely to be of benefit and is generally not used in this setting.",
"   </p>",
"   <p>",
"    Cephalocentesis, which almost always results in fetal death, is rarely used to decompress the head, allow vaginal delivery, and avoid maternal morbidity from cesarean delivery. We suggest its use in cases in which the neurological prognosis is so dismal (eg, trisomy 13 or 18 or lethal co-existent anomalies) that, if the fetus does not succumb from the procedure, the outcome will not be substantially changed. From an ethical standpoint, the physician's beneficence-based obligation to the pregnant woman allows her to avoid the increased risks of cesarean delivery in cases in which such management would be of little benefit to the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cephalocentesis is performed by making an incision at the base of the skull with a sharp instrument (eg, curved Mayo scissors), inserting a cannula, and then applying suction internally to collapse the calvarium [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     RECURRENCE RISK AND GENETIC COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Couples with an affected child should receive genetic counseling and thorough evaluation because sometimes a generic diagnosis of congenital ventriculomegaly may indicate a more complex diagnosis with significant genetic implications. As an example, patients at risk for X-linked hydrocephalus spectrum should be offered DNA diagnosis, as the recurrence risk is high (50 percent in males). In cases of isolated ventriculomegaly in which a precise cause is not determined, the recurrence risk is in the range of 4 percent, similar to that of other multifactorial disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/13\">",
"     13",
"    </a>",
"    ]. For cases of mild, isolated ventriculomegaly in which the infant is normal at birth and no associated abnormalities were identified, a complete postnatal genetic work-up is not indicated in most cases.",
"   </p>",
"   <p>",
"    We recommend detailed ultrasound examination at 18 to 20 weeks of gestation in a future pregnancy to look for recurrence. However, it has been noted that in some cases ventriculomegaly may develop late in gestation or after birth, so a normal mid-trimester ultrasound does not definitively rule out this diagnosis. As an example, mid-trimester sonography will not detect all fetuses with X-linked hydrocephalus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12920/abstract/65\">",
"     65",
"    </a>",
"    ]. For some diagnoses, such as polymicrogyria, fetal MRI is appropriate, as it may detect these relatively subtle brain abnormalities not diagnosable by sonographic examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the second or third trimester of pregnancy, the diagnosis of fetal ventriculomegaly is based upon ventricular dilation &ge;10 mm. The diagnosis of hydrocephalus is reserved for those cases where obstruction is visualized or can be inferred. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition and nomenclature'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the following diagnostic evaluation when fetal ventriculomegaly is detected: (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Obstetrical issues'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A comprehensive fetal sonogram to look for associated anomalies",
"     </li>",
"     <li>",
"      A detailed family and medical history to look for possible genetic or infectious causes of ventriculomegaly",
"     </li>",
"     <li>",
"      Fetal karyotype",
"     </li>",
"     <li>",
"      Testing for infectious etiologies (cytomegalovirus [CMV] and toxoplasmosis) ideally by polymerase chain reaction (PCR) on amniotic fluid or, alternatively, by maternal serology.",
"     </li>",
"     <li>",
"      Consideration of fetal magnetic resonance imaging for isolated ventriculomegaly in which the etiology is unexplained.",
"     </li>",
"     <li>",
"      A follow-up ultrasound examination to assess progression or regression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most children with isolated, mild ventriculomegaly have a normal outcome. The risk of abnormal outcome increases with the severity of ventriculomegaly, progression of ventriculomegaly, and presence of other anomalies. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fetuses with a normal head circumference may undergo vaginal delivery with cesarean delivery reserved for the usual obstetrical indications. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Delivery management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recurrence risk ranges from 4 to 50 percent, depending upon the cause. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Recurrence risk and genetic counseling'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/1\">",
"      Griffiths PD, Reeves MJ, Morris JE, et al. A prospective study of fetuses with isolated ventriculomegaly investigated by antenatal sonography and in utero MR imaging. AJNR Am J Neuroradiol 2010; 31:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/2\">",
"      Cardoza JD, Goldstein RB, Filly RA. Exclusion of fetal ventriculomegaly with a single measurement: the width of the lateral ventricular atrium. Radiology 1988; 169:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/3\">",
"      Pilu G, Reece EA, Goldstein I, et al. Sonographic evaluation of the normal developmental anatomy of the fetal cerebral ventricles: II. The atria. Obstet Gynecol 1989; 73:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/4\">",
"      Farrell TA, Hertzberg BS, Kliewer MA, et al. Fetal lateral ventricles: reassessment of normal values for atrial diameter at US. Radiology 1994; 193:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/5\">",
"      Davis GH. Fetal hydrocephalus. Clin Perinatol 2003; 30:531.",
"     </a>",
"    </li>",
"    <li>",
"     Menkes, JH, Sarnat, HB. Neuroembryology, Genetic Programming, and Malformations. In: Child Neurology, 6th ed, Menkes JH, Sarnat HB (Eds), Lippincott Williams and Wilkins, Philadelphia 2000. p. 354.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/7\">",
"      Partington MD. Congenital hydrocephalus. Neurosurg Clin N Am 2001; 12:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/8\">",
"      Hannon T, Tennant PW, Rankin J, Robson SC. Epidemiology, natural history, progression, and postnatal outcome of severe fetal ventriculomegaly. Obstet Gynecol 2012; 120:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/9\">",
"      Alagappan R, Browning PD, Laorr A, McGahan JP. Distal lateral ventricular atrium: reevaluation of normal range. Radiology 1994; 193:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/10\">",
"      Achiron R, Schimmel M, Achiron A, Mashiach S. Fetal mild idiopathic lateral ventriculomegaly: is there a correlation with fetal trisomy? Ultrasound Obstet Gynecol 1993; 3:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/11\">",
"      Melchiorre K, Bhide A, Gika AD, et al. Counseling in isolated mild fetal ventriculomegaly. Ultrasound Obstet Gynecol 2009; 34:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/12\">",
"      Chasen ST, Chervenak FA, McCullough LB. The role of cephalocentesis in modern obstetrics. Am J Obstet Gynecol 2001; 185:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/13\">",
"      V&aacute;radi V, T&oacute;th Z, T&ouml;r&ouml;k O, Papp Z. Heterogeneity and recurrence risk for congenital hydrocephalus (ventriculomegaly): a prospective study. Am J Med Genet 1988; 29:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/14\">",
"      Levine D, Feldman HA, Tannus JF, et al. Frequency and cause of disagreements in diagnoses for fetuses referred for ventriculomegaly. Radiology 2008; 247:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/15\">",
"      Benacerraf BR, Shipp TD, Bromley B, Levine D. What does magnetic resonance imaging add to the prenatal sonographic diagnosis of ventriculomegaly? J Ultrasound Med 2007; 26:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/16\">",
"      Cardoza JD, Filly RA, Podrasky AE. The dangling choroid plexus: a sonographic observation of value in excluding ventriculomegaly. AJR Am J Roentgenol 1988; 151:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/17\">",
"      Pretorius DH, Drose JA, Manco-Johnson ML. Fetal lateral ventricular ratio determination during the second trimester. J Ultrasound Med 1986; 5:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/18\">",
"      Pilu G, De Palma L, Romero R, et al. The fetal subarachnoid cisterns: an ultrasound study with report of a case of congenital communicating hydrocephalus. J Ultrasound Med 1986; 5:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/19\">",
"      Hilpert PL, Hall BE, Kurtz AB. The atria of the fetal lateral ventricles: a sonographic study of normal atrial size and choroid plexus volume. AJR Am J Roentgenol 1995; 164:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/20\">",
"      Achiron R, Yagel S, Rotstein Z, et al. Cerebral lateral ventricular asymmetry: is this a normal ultrasonographic finding in the fetal brain? Obstet Gynecol 1997; 89:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/21\">",
"      Senat MV, Bernard JP, Schw&auml;rzler P, et al. Prenatal diagnosis and follow-up of 14 cases of unilateral ventriculomegaly. Ultrasound Obstet Gynecol 1999; 14:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/22\">",
"      Sadan S, Malinger G, Schweiger A, et al. Neuropsychological outcome of children with asymmetric ventricles or unilateral mild ventriculomegaly identified in utero. BJOG 2007; 114:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/23\">",
"      Durfee SM, Kim FM, Benson CB. Postnatal outcome of fetuses with the prenatal diagnosis of asymmetric hydrocephalus. J Ultrasound Med 2001; 20:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/24\">",
"      Kinzler WL, Smulian JC, McLean DA, et al. Outcome of prenatally diagnosed mild unilateral cerebral ventriculomegaly. J Ultrasound Med 2001; 20:257.",
"     </a>",
"    </li>",
"    <li>",
"     Pilu, G, Falco, P, Perolo, A, Visentin, A. Ultrasound evaluation of the fetal eural Axis. In: Ultrasonography in Obstetrics and Gynecology, 4th ed, Callen, PE (Ed), W.B. Saunders Co., Philadelphia 2000. p. 279.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/26\">",
"      Fong K, Chong K, Toi A, et al. Fetal ventriculomegaly secondary to isolated large choroid plexus cysts: prenatal findings and postnatal outcome. Prenat Diagn 2011; 31:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/27\">",
"      Gaglioti P, Danelon D, Bontempo S, et al. Fetal cerebral ventriculomegaly: outcome in 176 cases. Ultrasound Obstet Gynecol 2005; 25:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/28\">",
"      Gaglioti P, Oberto M, Todros T. The significance of fetal ventriculomegaly: etiology, short- and long-term outcomes. Prenat Diagn 2009; 29:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/29\">",
"      Sethna F, Tennant PW, Rankin J, C Robson S. Prevalence, natural history, and clinical outcome of mild to moderate ventriculomegaly. Obstet Gynecol 2011; 117:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/30\">",
"      Jamieson DJ, Kourtis AP, Bell M, Rasmussen SA. Lymphocytic choriomeningitis virus: an emerging obstetric pathogen? Am J Obstet Gynecol 2006; 194:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/31\">",
"      Bonthius DJ, Wright R, Tseng B, et al. Congenital lymphocytic choriomeningitis virus infection: spectrum of disease. Ann Neurol 2007; 62:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/32\">",
"      Malinger G, Lev D, Zahalka N, et al. Fetal cytomegalovirus infection of the brain: the spectrum of sonographic findings. AJNR Am J Neuroradiol 2003; 24:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/33\">",
"      Chow KC, Lee CC, Lin TY, et al. Congenital enterovirus 71 infection: a case study with virology and immunohistochemistry. Clin Infect Dis 2000; 31:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/34\">",
"      Seidman DS, Nass D, Mendelson E, et al. Prenatal ultrasonographic diagnosis of fetal hydrocephalus due to infection with parainfluenza virus type 3. Ultrasound Obstet Gynecol 1996; 7:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/35\">",
"      Katz VL, McCoy MC, Kuller JA, Hansen WF. An association between fetal parvovirus B19 infection and fetal anomalies: a report of two cases. Am J Perinatol 1996; 13:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/36\">",
"      Sarnat HB. Ependymal reactions to injury. A review. J Neuropathol Exp Neurol 1995; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/37\">",
"      Bromley B, Frigoletto FD Jr, Benacerraf BR. Mild fetal lateral cerebral ventriculomegaly: clinical course and outcome. Am J Obstet Gynecol 1991; 164:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/38\">",
"      Tomlinson MW, Treadwell MC, Bottoms SF. Isolated mild ventriculomegaly: associated karyotypic abnormalities and in utero observations. J Matern Fetal Med 1997; 6:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/39\">",
"      Blaicher W, Prayer D, Mittermayer C, et al. The clinical impact of magnetic resonance imaging in fetuses with central nervous system anomalies on ultrasound scan. Ultraschall Med 2005; 26:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/40\">",
"      Levine D, Barnes PD, Robertson RR, et al. Fast MR imaging of fetal central nervous system abnormalities. Radiology 2003; 229:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/41\">",
"      Simon EM, Goldstein RB, Coakley FV, et al. Fast MR imaging of fetal CNS anomalies in utero. AJNR Am J Neuroradiol 2000; 21:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/42\">",
"      Whitby EH, Paley MN, Sprigg A, et al. Comparison of ultrasound and magnetic resonance imaging in 100 singleton pregnancies with suspected brain abnormalities. BJOG 2004; 111:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/43\">",
"      Griffiths PD, Paley MN, Widjaja E, et al. In utero magnetic resonance imaging for brain and spinal abnormalities in fetuses. BMJ 2005; 331:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/44\">",
"      Ouahba J, Luton D, Vuillard E, et al. Prenatal isolated mild ventriculomegaly: outcome in 167 cases. BJOG 2006; 113:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/45\">",
"      Parazzini C, Righini A, Doneda C, et al. Is fetal magnetic resonance imaging indicated when ultrasound isolated mild ventriculomegaly is present in pregnancies with no risk factors? Prenat Diagn 2012; 32:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/46\">",
"      Morris JE, Rickard S, Paley MN, et al. The value of in-utero magnetic resonance imaging in ultrasound diagnosed foetal isolated cerebral ventriculomegaly. Clin Radiol 2007; 62:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/47\">",
"      Salomon LJ, Ouahba J, Delezoide AL, et al. Third-trimester fetal MRI in isolated 10- to 12-mm ventriculomegaly: is it worth it? BJOG 2006; 113:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/48\">",
"      Levine D, Kazan-Tannus JF, Metha TS, et al. OC15: Concordance of prenatal ultrasound and MR diagnoses in fetuses referred for ventriculomegaly. Ultrasound Obstet Gynecol. 2007; 30:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/49\">",
"      Valsky DV, Ben-Sira L, Porat S, et al. The role of magnetic resonance imaging in the evaluation of isolated mild ventriculomegaly. J Ultrasound Med 2004; 23:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/50\">",
"      Graham E, Duhl A, Ural S, et al. The degree of antenatal ventriculomegaly is related to pediatric neurological morbidity. J Matern Fetal Med 2001; 10:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/51\">",
"      Manning FA, Harrison MR, Rodeck C. Catheter shunts for fetal hydronephrosis and hydrocephalus. Report of the International Fetal Surgery Registry. N Engl J Med 1986; 315:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/52\">",
"      von Koch CS, Gupta N, Sutton LN, Sun PP. In utero surgery for hydrocephalus. Childs Nerv Syst 2003; 19:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/53\">",
"      Signorelli M, Tiberti A, Valseriati D, et al. Width of the fetal lateral ventricular atrium between 10 and 12 mm: a simple variation of the norm? Ultrasound Obstet Gynecol 2004; 23:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/54\">",
"      Laskin MD, Kingdom J, Toi A, et al. Perinatal and neurodevelopmental outcome with isolated fetal ventriculomegaly: a systematic review. J Matern Fetal Neonatal Med 2005; 18:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/55\">",
"      Vergani P, Locatelli A, Strobelt N, et al. Clinical outcome of mild fetal ventriculomegaly. Am J Obstet Gynecol 1998; 178:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/56\">",
"      Pilu G, Falco P, Gabrielli S, et al. The clinical significance of fetal isolated cerebral borderline ventriculomegaly: report of 31 cases and review of the literature. Ultrasound Obstet Gynecol 1999; 14:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/57\">",
"      Goldstein RB, La Pidus AS, Filly RA, Cardoza J. Mild lateral cerebral ventricular dilatation in utero: clinical significance and prognosis. Radiology 1990; 176:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/58\">",
"      Bloom SL, Bloom DD, DellaNebbia C, et al. The developmental outcome of children with antenatal mild isolated ventriculomegaly. Obstet Gynecol 1997; 90:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/59\">",
"      Leitner Y, Stolar O, Rotstein M, et al. The neurocognitive outcome of mild isolated fetal ventriculomegaly verified by prenatal magnetic resonance imaging. Am J Obstet Gynecol 2009; 201:215.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/60\">",
"      Beeghly M, Ware J, Soul J, et al. Neurodevelopmental outcome of fetuses referred for ventriculomegaly. Ultrasound Obstet Gynecol 2010; 35:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/61\">",
"      Futagi Y, Suzuki Y, Toribe Y, Morimoto K. Neurodevelopmental outcome in children with fetal hydrocephalus. Pediatr Neurol 2002; 27:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/62\">",
"      Breeze AC, Alexander PM, Murdoch EM, et al. Obstetric and neonatal outcomes in severe fetal ventriculomegaly. Prenat Diagn 2007; 27:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/63\">",
"      Gilmore JH, Smith LC, Wolfe HM, et al. Prenatal mild ventriculomegaly predicts abnormal development of the neonatal brain. Biol Psychiatry 2008; 64:1069.",
"     </a>",
"    </li>",
"    <li>",
"     Hammond C, Chasen S. Dilation and evacuation. In: Paul M, editor. Management of unintended and abnormal pregnancy. West Sussex, UK: Wiley Blackwell; 2009, p. 173.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12920/abstract/65\">",
"      Jouet M, Kenwrick S. Gene analysis of L1 neural cell adhesion molecule in prenatal diagnosis of hydrocephalus. Lancet 1995; 345:161.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6784 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-BC8603A877-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_39_12920=[""].join("\n");
var outline_f12_39_12920=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION AND NOMENCLATURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PRENATAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Atrial assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Asymmetry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OBSTETRICAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Initial work-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Comprehensive sonographic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Review of medical history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Amniocentesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Evaluation for infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Delivery management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      RECURRENCE RISK AND GENETIC COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6784\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6784|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/63/25585\" title=\"diagnostic image 1\">",
"      Mild fetal ventriculomegaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/37/42581\" title=\"diagnostic image 2\">",
"      Fetal hydrocephaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6784|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/40/37510\" title=\"figure 1\">",
"      Direction of flow of cerebrospinal fluid",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15417?source=related_link\">",
"      Aseptic meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12634?source=related_link\">",
"      Cytomegalovirus infection in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/54/5994?source=related_link\">",
"      Hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/44/2762?source=related_link\">",
"      Prenatal diagnosis of CNS anomalies other than neural tube defects and ventriculomegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25145?source=related_link\">",
"      Prenatal screening and diagnosis of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=related_link\">",
"      Sonographic findings associated with fetal aneuploidy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=related_link\">",
"      Toxoplasmosis and pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_39_12921="Hypopigmented sarcoidosis";
var content_f12_39_12921=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74163%7EDERM%2F63313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74163%7EDERM%2F63313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypopigmented sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hypopigmented sarcoidosis. Discrete, hypopigmented macules and patches are present on the trunk. Some lesions demonstrate central papules, which resemble the configuration of a fried egg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypopigmented sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hypopigmented sarcoidosis. Discrete, hypopigmeted macules with central papules are present. The lesions resemble the configuration of a fried egg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_39_12921=[""].join("\n");
var outline_f12_39_12921=null;
var title_f12_39_12922="Adult lead poisoning";
var content_f12_39_12922=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adult lead poisoning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/39/12922/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/39/12922/contributors\">",
"     Rose H Goldman, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/39/12922/contributors\">",
"     Howard Hu, ScD, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/39/12922/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/39/12922/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/39/12922/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/39/12922/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/39/12922/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lead poisoning can present with nonspecific signs and symptoms such as abdominal pain, constipation, irritability, difficulty concentrating, and anemia. Clinicians need to consider this diagnosis and know the appropriate tests to order for documenting exposure and assessing for early health effects. It is also now well-established that chronic exposure to modest levels of lead, too low to trigger symptoms, can increase risk for hypertension and accelerated future cognitive and renal decline in adults.",
"   </p>",
"   <p>",
"    Clinicians need to know how to play a proactive role in early detection and prevention by screening patients known to work in occupations with possible lead exposure, and what actions to take when excessive exposure is found. The costs and consequences of lead poisoning can be entirely prevented by eliminating and decreasing sources of exposures and by early recognition of elevated lead levels or lead poisoning.",
"   </p>",
"   <p>",
"    Some of the clinical conditions related to lead poisoning and issues related to lead poisoning in children are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6138?source=see_link\">",
"     \"Clinical aspects, diagnosis, and treatment of the sideroblastic anemias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5705?source=see_link\">",
"     \"Lead nephropathy and lead-related nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIMENSIONS OF THE PROBLEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The true extent of adult lead poisoning in the United States (US) is difficult to measure because of limited data. One source of data is the Centers for Disease Control's (CDC's) Adult Blood Lead Epidemiology and Surveillance (ABLES) program that monitors laboratory reported elevated blood lead levels (BLL) [defined as greater than or equal to 25",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (1.21",
"    <span class=\"nowrap\">",
"     micromol/L)]",
"    </span>",
"    among adults in 40 states [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ABLES surveillance results indicate an overall decrease in the national prevalence of elevated BLL's from 14.0 per 100,000 in 1994 to 6.3 in 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/2\">",
"     2",
"    </a>",
"    ]. Ninety-four percent of the adults with an identified exposure source were exposed at work. These work exposures occurred mainly in battery manufacturing, lead and zinc ore mining, and painting and paper hanging industry subsectors.",
"   </p>",
"   <p>",
"    Data from another source, the National Health and Nutrition Examination Survey (NHANES) provides information on the percentage of persons with elevated blood lead levels (here defined as greater than or equal to 10",
"    <span class=\"nowrap\">",
"     mcg/dL),",
"    </span>",
"    and mean lead levels for the US population of different ages, genders, and",
"    <span class=\"nowrap\">",
"     racial/ethnic",
"    </span>",
"    populations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The NHANES data show a decline in the overall geometric mean blood level for the adult population (greater than 20 years) in the US from approximately 13",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.63",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in 1976 to 1980, to 1.38",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.067",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in 2007-2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additionally, the NHANES data show a decrease in the percentage of adults with blood lead levels &ge;10",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.48",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    from 3.1 percent (ages 20 to 59) and 6.5 percent (&gt;60 years) in the 1991 to 1994 survey, to 0.7 percent (ages 20 to 59) and 0.8 (age 60) in the 1999 to 2002 survey [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/3\">",
"     3",
"    </a>",
"    ]. The 2007-2008 survey also reported higher prevalence rates of elevated blood lead levels in adult males compared to females, and among non-Hispanic blacks compared to non-Hispanic whites [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/3\">",
"     3",
"    </a>",
"    ]. The disparities are less than observed in prior surveys.",
"   </p>",
"   <p>",
"    Despite these apparent improvements in the US, greater prevention activities, particularly in work environments, will be needed to achieve the previous US 2010 health objective to reduce to zero the number of adults with blood lead levels &ge;25",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (1.21",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    Additionally, there are also concerns about long-term exposures at blood lead levels below this level [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/5\">",
"     5",
"    </a>",
"    ]. The current US Healthy People 2020 objectives no longer address goals for adult blood lead levels, but do so for children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11001?source=see_link\">",
"     \"Childhood lead poisoning: Exposure and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sources of exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of adult elevated blood lead levels come from work place exposures (",
"    <a class=\"graphic graphic_table graphicRef53953 \" href=\"UTD.htm?9/3/9277\">",
"     table 1",
"    </a>",
"    ). Lead exposure can occur in numerous work settings, such as manufacturing or use of batteries, pigments, solder, ammunitions, paint, car radiators, cable and wires, some cosmetics, ceramic ware with lead glazes, and tin cans [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/7\">",
"     7",
"    </a>",
"    ]. Primary and secondary lead smelting and refinement are associated with considerable exposure.",
"   </p>",
"   <p>",
"    An organic form of lead (tetraethyl lead) was added to gasoline to raise the octane level and to serve as an \"antiknock\" agent in the 1920s. It has been estimated that 90 percent of atmospheric lead originated from automobile exhaust and accounted for the increase in environmental lead concentrations observed between the 1930s and 1960s (",
"    <a class=\"graphic graphic_figure graphicRef60319 \" href=\"UTD.htm?24/52/25422\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The introduction of lead-free gasoline in the 1980s contributed to a considerable decrease in air lead levels in the US and consequently blood lead levels [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. However, leaded gasoline continues to be used in many parts of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mass lead intoxication has been reported for both children and adults living around and working in lead battery",
"    <span class=\"nowrap\">",
"     manufacturing/recycling",
"    </span>",
"    plants, particularly in developing compared to developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of lead paint has resulted in lead exposures at work in the construction trades [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/15\">",
"     15",
"    </a>",
"    ] as well as in the home, thereby posing a lead poisoning risk to children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/16\">",
"     16",
"    </a>",
"    ]. The lead content of paint was unregulated until 1977. It is estimated that about one million construction workers in the US are occupationally exposed to lead [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition to coating residential properties, lead paint also covers five billion square feet of nonresidential surface area in the US, including 89 percent of the nation's steel bridges [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/15\">",
"     15",
"    </a>",
"    ]. Lead can also enter the environment and increase soil lead levels when natural disasters destroy homes, as in the case of Hurricane Katrina in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An additional source of lead exposure has been identified as lead dust deposited on radiographs stored in lead-lined boxes. A study performed by the Wisconsin Division of Public health found that patients are at risk for substantial lead exposure during a dental radiograph if the office stores the films in these boxes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some parts of the US, illegally distilled alcohol (\"moonshine\") is an important source of lead exposure. As an example, in a study from an emergency department in Atlanta, 8.6 percent of adult patients reported consuming moonshine in the past five years, and the median blood lead level in drinkers of moonshine was significantly higher than in nondrinkers, 11.0 versus 2.5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.53 versus 0.12",
"    <span class=\"nowrap\">",
"     micromol/L);",
"    </span>",
"    the percentage of patients with blood lead levels &ge;25",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (1.21",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    was higher as well (25.7 versus 0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/19\">",
"     19",
"    </a>",
"    ]. Lead has also been found as an adulterant in marijuana [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lead poisoning has occurred in those taking Ayurvedic medications, including during pregnancy, and in those cooking or eating off of lead-glazed tableware and cookware [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/21-26\">",
"     21-26",
"    </a>",
"    ]. Litargirio (also known as litharge or lead monoxide), a lead-based powder sold and used in some Hispanic communities as an",
"    <span class=\"nowrap\">",
"     antiperspirant/deodorant",
"    </span>",
"    and as a folk remedy, has also caused lead poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/27\">",
"     27",
"    </a>",
"    ], as has the use of tiro, an eye cosmetic from Nigeria [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/28\">",
"     28",
"    </a>",
"    ]. Women who reported using herbal supplements had blood lead levels 10 percent higher than non-users, although mean lead levels were low in both groups [&lt;2.0",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.97",
"    <span class=\"nowrap\">",
"     micromol/L)]",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/29\">",
"     29",
"    </a>",
"    ]. Blood lead levels were about 20 percent higher for those women reporting use of Ayurvedic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    traditional Chinese medicine herbs, as well as St. John's wort, compared to non-users.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     BIOLOGICAL BASIS FOR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inorganic lead is absorbed from the lungs or gastrointestinal tract. In adults, absorption of lead via the respiratory tract is the most significant route of entry, with an average absorption rate of approximately 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/8\">",
"     8",
"    </a>",
"    ]. Respiratory exposures can occur with activities such as",
"    <span class=\"nowrap\">",
"     scraping/sanding/burning",
"    </span>",
"    leaded paint from surfaces as well as from various",
"    <span class=\"nowrap\">",
"     smelting/burning",
"    </span>",
"    processes. Organic (tetraethyl) lead that is found in gasoline can be absorbed via the skin.",
"   </p>",
"   <p>",
"    The efficacy of gastrointestinal (GI) absorption of lead in adults is about 10 to 15 percent and is increased during fasting when diets are deficient in calcium, iron, phosphorous or zinc. Although GI absorption is not the major route for adults, it can be a significant contributor, particularly when working",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    eating in a lead-contaminated environment. GI absorption is the predominate route in children, and is more efficient, estimated to be around 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once absorbed, lead is then distributed to the blood, soft tissues, and skeleton. In blood, 99 percent of lead is bound to the erythrocyte and the remaining 1 percent is free in the plasma to exchange with soft tissues (kidney, brain, liver, bone marrow). Lead in blood is excreted via the kidneys and cleared comparatively fast, with a mean half-life of about 30 days if renal function is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/30\">",
"     30",
"    </a>",
"    ]. However, blood clearance can be slower in people with a long history of lead exposure and large bone stores [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lead in the skeleton has a half-life of decades and contains approximately 95 percent of the body burden of lead [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/30\">",
"     30",
"    </a>",
"    ]. Lead can be released from this bone reservoir during times of bone turnover, such as during hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/32\">",
"     32",
"    </a>",
"    ], menopause, pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/33\">",
"     33",
"    </a>",
"    ], and breast feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lead is a toxic metal that affects many functions and organ systems in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Some of the biochemical mechanisms of lead toxicity are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lead is an electropositive metal. Its high affinity for negatively charged sulfhydryl groups leads to the inhibition of sulfhydryl dependent enzymes such as gamma-aminolevulinic acid dehydratase (ALA-D) and ferrochelatase in heme synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/8\">",
"       8",
"      </a>",
"      ]. This disruption of hemoglobin synthesis leads to the production of free erythrocyte protoporphyrins that can be measured. Anemia can develop at very high blood lead levels (usually greater than",
"      <span class=\"nowrap\">",
"       80ug/dL).",
"      </span>",
"      In addition, lead inhibition of pyrimidine 5&rsquo; nucleotidase can cause degradation of ribosomal RNA in red blood cells that can lead to the appearance of basophilic stippling on a peripheral smear [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The divalent lead also acts competitively with calcium in several biologic systems, such as mitochondrial respiration and various nerve functions. Lead's interference with several calcium dependent processes and activation of protein kinase C has been implicated as a contributing mechanism in neurotoxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lead alters the permeability of the blood brain barrier and accumulates in astroglia, cells essential for maintenance of the neuronal environment [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lead can also affect nucleic acids, deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) by mechanisms not yet fully understood. Some studies indicate that lead exposure may alter global DNA methylation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/37\">",
"       37",
"      </a>",
"      ]. One observational study demonstrated that high lead exposure was associated with telomere length shortening in Chinese battery manufacturing plant workers [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/38\">",
"       38",
"      </a>",
"      ]. A shortened telomere can result in genomic instability, which epidemiological investigations have linked to a number of adverse outcomes, such as decreased life expectancy, increased cancer risk, and cardiovascular diseases. &nbsp;",
"     </li>",
"     <li>",
"      Lead has effects on cell membranes, interfering with various energy and transport systems, which may explain effects such as shortened erythrocyte survival time, hemolysis, and renal toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lead promotes generation of superoxide and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"       hydrogen peroxide",
"      </a>",
"      in human endothelial cells and vascular smooth muscle cells [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/39\">",
"       39",
"      </a>",
"      ], which may explain effects on blood pressure. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence is beginning to emerge that some common genetic polymorphisms may predispose individuals to worse responses to lead exposure. As an example, the allele for hemochromatosis (C282Y or H63D), even if in heterozygous carriers without risk for clinical hemochromatosis, has been shown to be associated with worse cognitive declines given the same cumulative exposure to lead [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the toxic effects of lead are reversible if lead poisoning is identified early. However, high level lead poisoning, or moderate poisoning over long periods, can result in irreversible damage to the central and peripheral nervous systems and kidneys.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Acute exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unrecognized lead poisoning presenting with symptoms of colicky abdominal pain can be misdiagnosed and cause unnecessary gastrointestinal evaluation and abdominal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The manifestations of lead poisoning can vary from individual to individual. There is a general correlation between acute health effects and blood lead levels (",
"    <a class=\"graphic graphic_figure graphicRef63076 \" href=\"UTD.htm?41/6/42081\">",
"     figure 2",
"    </a>",
"    ). Severe lead poisoning is seen with blood lead levels generally above 80",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (3.86",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    Acute poisoning can present with a number of signs and symptoms, including the following [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/7,42\">",
"     7,42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal pain (\"lead colic\")",
"     </li>",
"     <li>",
"      Constipation",
"     </li>",
"     <li>",
"      Joint pains",
"     </li>",
"     <li>",
"      Muscle aches",
"     </li>",
"     <li>",
"      Headache",
"     </li>",
"     <li>",
"      Anorexia",
"     </li>",
"     <li>",
"      Decreased libido",
"     </li>",
"     <li>",
"      Difficulty concentrating and deficits in short-term memory",
"     </li>",
"     <li>",
"      Anemia",
"     </li>",
"     <li>",
"      Nephropathy (Fanconi-type syndrome)",
"     </li>",
"     <li>",
"      A \"lead line,\" a bluish pigmentation seen at the gum-tooth line, is not a sensitive finding, and is the result of a reaction of lead with dental plaque (",
"      <a class=\"graphic graphic_picture graphicRef68115 \" href=\"UTD.htm?23/33/24095\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Basophilic stippling on blood smear may be seen (",
"      <a class=\"graphic graphic_picture graphicRef71989 \" href=\"UTD.htm?39/22/40294\">",
"       picture 2",
"      </a>",
"      ). However, this is an inconsistent and nonspecific sign of lead poisoning [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A peripheral neuropathy that frequently manifests with extensor weakness or",
"      <span class=\"nowrap\">",
"       \"wrist/ankle",
"      </span>",
"      drop\" due to an axonal degeneration that primarily affects motor nerves [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/44\">",
"       44",
"      </a>",
"      ]. This is seen less frequently since governmental regulations have resulted in lower lead exposures at work.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chronic exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adults with lower level, chronic or recurrent exposures with blood lead levels in the 30 to 70",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    range (1.45 to 3.38",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    may be asymptomatic or present with vague nonspecific symptoms such as myalgias, fatigue, irritability, insomnia, anorexia, impaired short-term memory, and difficulty concentrating.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be an association between blood and bone lead levels and blood pressure, but the magnitude of this effect is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/45-50\">",
"     45-50",
"    </a>",
"    ]. The association between blood lead levels and blood pressure was assessed in a meta-analysis of studies in the general population and in individuals with occupational lead exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/45\">",
"     45",
"    </a>",
"    ]. It was estimated that a two-fold increase in blood lead levels was associated with a small but significant increase in blood pressure of",
"    <span class=\"nowrap\">",
"     1.0/0.6",
"    </span>",
"    mmHg.",
"   </p>",
"   <p>",
"    Bone lead, a reflection of cumulative lead exposure, may be more closely associated with the development of hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/48,50\">",
"     48,50",
"    </a>",
"    ]. In a report from the Normative Aging Study, it was estimated that an increase from the lowest to the highest quintile of tibial lead was, in a logistic regression model, an independent risk factor for the development of hypertension (OR 1.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/48\">",
"     48",
"    </a>",
"    ]. Blood lead was not an independent risk factor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Neuropsychiatric effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic (cumulative) lead exposure has also been associated with a number of other adverse health effects, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Declines in neurocognitive functioning [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/51-54\">",
"       51-54",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Psychiatric symptoms (phobic anxiety, depression, and hostility) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/55,56\">",
"       55,56",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Distal sensory and motor neuropathies [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Electrocardiographic conduction delays [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/57\">",
"       57",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, elevated lead levels are associated with structural changes in the brain, including white matter lesions and loss of brain volume [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/58\">",
"     58",
"    </a>",
"    ], and increased brain gliosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/59\">",
"     59",
"    </a>",
"    ] and electrocardiographic evidence of conduction delays [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/57\">",
"     57",
"    </a>",
"    ] have been described.",
"   </p>",
"   <p>",
"    Bone lead, which remains for decades, has been shown to be a better predictor than blood levels of long-term effects on cognitive function [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/51,60\">",
"     51,60",
"    </a>",
"    ]. In one of the longest known lead cohort studies available, bone lead level predicted lower cognitive performance over a 22 year period, particularly in workers older than age 55, whereas blood lead levels showed no association [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/51\">",
"     51",
"    </a>",
"    ]. Another study found that cumulative lead exposure may increase the risk of Parkinson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Reproductive effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In recent decades attention has focused upon the effect of lead on the reproductive system. Lead readily crosses the placenta. Increased number of miscarriages and stillbirths appear to be related to high lead exposures in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/8\">",
"     8",
"    </a>",
"    ]. Reduced birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/62\">",
"     62",
"    </a>",
"    ] and cognitive impairments [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/63,64\">",
"     63,64",
"    </a>",
"    ] also have been reported in babies born to mothers with elevated lead in venous blood, cord blood, or bone. Bone lead levels have also been associated with higher maternal blood pressure and higher rates of third-trimester hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/65\">",
"     65",
"    </a>",
"    ]. Sources of maternal lead exposure may be current, or the result of mobilization from bone stores remaining from past exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/34,62\">",
"     34,62",
"    </a>",
"    ]. These effects have been seen at levels as low as 10 to 15",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.48 to 0.72",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    The effect of lead exposure during pregnancy on subsequent neurodevelopment of offspring is most apparent from exposure during the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/66\">",
"     66",
"    </a>",
"    ] and heightens the importance of preventing lead exposure as early as possible in pregnancy. (See",
"    <a class=\"local\" href=\"#H1318049\">",
"     'Pregnancy and breastfeeding'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Men with chronic lead exposure [and blood lead levels between 40 and 70",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (1.93 to 3.38",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    have been found in some studies to have an increased percent of sperm with abnormal morphology and decreased sperm concentration, total sperm count, and total motile sperm count [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/67-69\">",
"     67-69",
"    </a>",
"    ], as well as alterations of male endocrine function [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic exposure with low lead levels 20 to 29",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.97 to 1.40",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/71\">",
"     71",
"    </a>",
"    ], and even less than 10",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.48",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/72\">",
"     72",
"    </a>",
"    ], has been linked to an increase in mortality. In a nationally representative sample in the US, blood lead levels &gt;10",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (median 11.8",
"    <span class=\"nowrap\">",
"     mcg/dL)",
"    </span>",
"    were associated with an increased risk of death from all causes (RR 1.59, 95% CI 1.28-1.98), cardiovascular disease (RR 1.55, 95% CI 1.16-2.07), and cancer (RR 1.69, 95% CI 1.14-2.52) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective cohort of 868 lead-exposed men in the Normative Aging Study followed over 8.9 years, those in the highest tertile for bone lead concentration were at higher risk of all-cause mortality (HR 2.5, 95% CI 1.2-5.4) and cardiovascular mortality (HR 5.63, 95% CI 1.7-18.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/74\">",
"     74",
"    </a>",
"    ]. Blood lead level was not associated with mortality in this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lead exposure may also affect the kidney and accelerate aging-related diseases related to vision, hearing, and dental health. There are likely other effects, including some evidence that lead exposure may be carcinogenic.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lead nephropathy is a potential complication of prolonged high-level lead exposure. In addition, low levels of lead exposure have the potential for lead-related nephrotoxicity. These issues are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5705?source=see_link\">",
"       \"Lead nephropathy and lead-related nephrotoxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Low-level accumulated lead exposure, at levels commonly experienced by adults in the US, appears to be associated with an increased risk of cataract [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/75\">",
"       75",
"      </a>",
"      ], hearing loss [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/76\">",
"       76",
"      </a>",
"      ], tooth loss [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/77\">",
"       77",
"      </a>",
"      ], and gout [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some animal studies have found that inorganic lead is carcinogenic, particularly for renal tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/7\">",
"       7",
"      </a>",
"      ]. Epidemiological studies of workers have revealed mixed results regarding increased risks of cancer, and have suffered from lack of quantitative exposure information, information about contribution from smoking, and exposures to other metals. Although the human data are still not conclusive, the National Toxicology Program of the US Department of Health and Human Services determined that lead is a probable human carcinogen [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are few studies of the long-term consequences of childhood lead poisoning. However, in a 50-year follow-up of 35 adult survivors of childhood lead poisoning, cognitive dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/80\">",
"     80",
"    </a>",
"    ], hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/81\">",
"     81",
"    </a>",
"    ], and offspring with learning disabilities [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/82\">",
"     82",
"    </a>",
"    ] were more prevalent than in matched adult controls; the adults in this study had been symptomatic in childhood and thus likely had blood lead levels exceeding 60",
"    <span class=\"nowrap\">",
"     mcg/dL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of the adult with potential lead toxicity involves taking a",
"    <span class=\"nowrap\">",
"     medical/environmental",
"    </span>",
"    history to identify potential sources of exposure and symptoms consistent with lead poisoning, looking for signs on physical examination compatible with lead toxicity, documenting and measuring",
"    <span class=\"nowrap\">",
"     environmental/occupational",
"    </span>",
"    exposures (when possible), and examining laboratory evidence to confirm excessive lead exposure or organ system damage consistent with lead-related effects [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     occupational/environmental",
"    </span>",
"    history includes a job description, products manufactured, potential sources of lead exposure, engineering controls, the appropriate use and maintenance of personal protective equipment (including correct type of respirator that fits properly), housekeeping practices, smoking and eating at work (which can result in hand-to-mouth exposures), as well as attention to non-work exposures such as hobbies (including such activities as distillation of \"moonshine\" alcohol) or home repairs (",
"    <a class=\"graphic graphic_algorithm graphicRef81539 \" href=\"UTD.htm?27/26/28067\">",
"     algorithm 1",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14553?source=see_link\">",
"     \"Overview of occupational and environmental health\"",
"    </a>",
"    ). The timing of the symptoms, changes in frequency or intensity, and relationship to any changes or recent exposure conditions is helpful information. It is also important to note the past history of lead exposure on previous jobs, or childhood lead poisoning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key clinical monitoring test for diagnosing lead toxicity is the blood lead level. Measuring lead in urine, hair, or other media is not as accurate or reliable. The blood lead level is a good indicator of exposure that has occurred within the previous few weeks. In interpreting the results, it is important to use levels appropriate to adult toxicity, rather than children's (which sometimes are the ranges of concern reported by the testing laboratories).",
"   </p>",
"   <p>",
"    As discussed below, we tend to recommend chelation for individuals with blood lead levels greater than 80",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (3.86",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    and in some symptomatic individuals with levels as low as 50",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (2.42",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Chelation therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The other core laboratory tests that measure lead effects are the free erythrocyte protoporphyrin (FEP), complete blood count with blood smear morphology, blood urea nitrogen (BUN), serum creatinine, and urinalysis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The free erythrocyte protoporphyrin (FEP) or zinc protoporphyrin (ZPP) both measure the effect of lead on hemoglobin synthesis, and therefore either can be used as an indicator of lead exposure (and effect) over the preceding three-month period (determined by the average 120 day lifespan of the erythrocyte).",
"     </li>",
"     <li>",
"      If either the blood lead or FEP is elevated, then other tests for lead effect on blood (CBC with smear) and the kidneys (serum creatinine, urinalysis) should be performed. Blood smear morphology should also be obtained in the setting of anemia. We generally do not perform smear morphology for routine screening (given that abnormalities in the smear would be associated only with high lead levels and are not specific). Smear morphology is required as part of medical surveillance for workers covered by the Occupational Safety Health Administration (OSHA) regulations promulgated in 1978 [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/83\">",
"       83",
"      </a>",
"      ] and for construction workers in 1993 [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/84\">",
"       84",
"      </a>",
"      ]. These guidelines have not been updated.",
"     </li>",
"     <li>",
"      It is important to note that the serum creatinine is not a sensitive indicator of renal damage since it does not rise substantially in patients with normal baseline values until over 50 percent of kidney function is lost. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link\">",
"       \"Assessment of kidney function\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5705?source=see_link\">",
"       \"Lead nephropathy and lead-related nephrotoxicity\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abdominal radiographs, which are often ordered in children to look for evidence of lead ingestion, are not appropriate for adults in whom the route of exposure is more commonly inhalation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Site of blood sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;For routine monitoring of occupational exposure to lead, venous blood sampling is preferable to earlobe capillary blood sampling. Surface skin contamination can result in false elevations in the lead level in sampled capillary blood even after the area is cleaned with an alcohol wipe [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A single blood lead level reflects both recent exposure to exogenous sources and the release of endogenous lead from bone and soft tissue stores. However, cumulative lead exposure from chronic low-level exposures has been recognized as a cause for concern [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/86\">",
"     86",
"    </a>",
"    ]. It is therefore important to keep a record of repeated measures of blood lead, from which a cumulative blood lead index (CBLI) can be calculated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/87\">",
"     87",
"    </a>",
"    ]. This parameter has been shown to closely parallel bone lead levels measured by x-ray fluorescence. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Other tests'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other tests which might be performed depending upon the setting and the patient's symptoms, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      X-ray fluorescence &mdash; Bone lead concentration measured by x-ray fluorescence (XRF) is a relatively new technology that can be used to make rapid, noninvasive measurements of lead in bone [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/88\">",
"       88",
"      </a>",
"      ]. In contrast to blood lead levels, the bone lead concentration reflects cumulative lead exposure, with an estimated half-life of 10 to 30 years [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/86,89\">",
"       86,89",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      XRF measurements have become increasingly standardized in terms of technique and interpretation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/87\">",
"       87",
"      </a>",
"      ]. However, XRF detection equipment remains available in only a few research centers and tends to be used primarily for research studies [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neurobehavioral testing &mdash; Neurobehavioral testing is indicated in cases in which there is persistent impairment of cognitive function and a history of elevated blood lead levels. Neurobehavioral testing can demonstrate changes in manual dexterity, perceptual motor speed, and memory deficits characteristic of lead poisoning, and can sometimes be helpful in distinguishing from other causes of cognitive dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/52,91\">",
"       52,91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nerve conduction velocity testing &mdash; Nerve conduction velocity testing should be considered when there are persistent symptoms or clinical findings suggestive of the presence of peripheral neuropathy, as well as a history of high blood lead levels, usually above 60",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (2.90",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      particularly if persistent for a long time period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of patients with elevated lead levels generally consists of removal of lead exposure and, in cases of high blood lead levels [usually &gt;50",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (2.42",
"    <span class=\"nowrap\">",
"     micromol/L)],",
"    </span>",
"    consideration of chelation therapy. In cases in which chelation therapy is being considered, it would be prudent to consult with a physician with expertise in treating adult lead poisoning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Reducing lead exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduction or removal from lead exposure is the key first step in treating all cases of excessive lead absorption. Removal from lead exposure when blood lead levels rise to 50",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (2.42",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    is mandated under the standards of the US Occupational Safety Health Administration (OSHA) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/83\">",
"     83",
"    </a>",
"    ]. Removal from lead exposure may be accomplished by transfer to another job in a lead-free area or, if not possible, by removal from work while receiving salary under \"medical removal protection.\" Workers can also be removed at lower levels if the treating clinician believes that the elevated lead level is responsible for adverse health effects.",
"   </p>",
"   <p>",
"    There are, however, growing concerns about cumulative effects of long-term exposures (over a working life) resulting in blood levels that remain above 10 to 20",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/5\">",
"     5",
"    </a>",
"    ]. Although not yet required by regulations, prudent health-based management would involve keeping long-term sustained blood lead concentrations over the working lifetime as low as possible; less than 20",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.97",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    and ideally below 10",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.48",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and under 5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.24",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    for pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/5,92\">",
"     5,92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Centers for Disease Control and Prevention (CDC) set a public health objective to eliminate blood lead levels &ge;25",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (1.21",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    by 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/93\">",
"     93",
"    </a>",
"    ]. In addition, workers with a blood lead level &ge;40",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (1.93",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    are required by OSHA to have an annual medical evaluation for the adverse effects related to lead exposure.",
"   </p>",
"   <p>",
"    When elevated blood lead levels are noted, actions can be taken at work to prevent further excessive exposures, such as implementing work practices that generate less lead dust, using engineering controls or personal protection (appropriate respirators, work clothes), hand washing, and other improved clean up practices. Given growing information about subclinical lead effects at blood lead levels less than 40",
"    <span class=\"nowrap\">",
"     mcg/dL,",
"    </span>",
"    efforts should be made to control exposures and get blood lead levels lower when found to be above 20",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.97",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/5,71\">",
"     5,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5705?source=see_link&amp;anchor=H9#H9\">",
"     \"Lead nephropathy and lead-related nephrotoxicity\", section on 'Lead-related nephrotoxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When efforts made to control exposures do not result in lowering blood lead levels below 20",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.97",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    a dilemma arises whether the clinician should advise an asymptomatic worker to leave work entirely to avoid continued low dose exposure and risks of future health effects. There is no simple answer. Removal from work may result in financial losses and hardship, given the lack of current regulatory protection for workers removed in order to protect against future adverse health effects. Different expert groups offer different guidance concerning removal from lead exposure, which may involve removal from the workplace [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/5,94\">",
"     5,94",
"    </a>",
"    ]. Clinicians will need to address each patient individually, taking into consideration medical history and risk factors, length of time expected to work with lead exposure, and incorporating financial and social factors into the decision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Chelation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, removal from exposure is the only therapy needed. However, chelation therapy may more rapidly decrease blood lead levels and relieve acute lead symptoms (such as lead colic). Unfortunately, there are no randomized clinical trials that have proven the efficacy of chelation on clinical outcomes, particularly long-term outcomes, in lead poisoned adults [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/95\">",
"     95",
"    </a>",
"    ]. Some studies have suggested improvement in central nervous system (CNS) symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/96\">",
"     96",
"    </a>",
"    ] and creatinine clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/97\">",
"     97",
"    </a>",
"    ] with chelation. The decision to treat with chelating agents becomes a judgment call based upon consideration of a number of factors, including presence of lead-related symptoms, current blood lead levels, duration of excessive lead exposure, duration of symptoms, and presence of other underlying medical problems [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/8,15\">",
"     8,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, chelation should be initiated for individuals with blood lead levels greater than 100",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (4.83",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    and should also be considered for levels between 80 to 100",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    in asymptomatic individuals and for blood lead levels between 50 to 80",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (2.41 to 3.86",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in individuals with lead-related symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, we sometimes consider chelation in persons with even lower blood lead levels [eg, &ge; 40",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (1.93",
"    <span class=\"nowrap\">",
"     micromol/L)]",
"    </span>",
"    if they have continued symptoms and elevated blood lead levels after two weeks of removal from exposure. Two chelating agents most commonly used to treat adults are DMSA and CaEDTA.",
"   </p>",
"   <p>",
"    Chelation with any agent should not be undertaken unless exposure has been definitively curtailed, since its use in the presence of continuing exposure may result in enhanced absorption of lead and worsening, rather than amelioration of toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     DMSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;DMSA (2,3-dimercaptosuccinic acid, succimer) is an oral chelation agent that is approved by the US Food and Drug Administration (FDA) for the treatment of lead-poisoned children, and has also been found effective in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. The recommended dose from the manufacturer is 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    three times per day for five days, followed by 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice per day for two weeks. Although we have found this dosing to be acceptable in treating some adults, the dose can become quite high, especially in heavier adults.",
"   </p>",
"   <p>",
"    Given the lack of adult treatment data with DMSA, we have also used an adult dosing level of 500 mg twice per day for two weeks as a sensible maximum limit until there are additional clinical data available for adults. The most common adverse side effects include abdominal distress, nausea, transient rash, elevated liver transaminase enzymes, and neutropenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Calcium EDTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium disodium ethylenediaminetetraacetate (CaEDTA) is an older chelating agent, introduced in the early 1950's, which must be administered intravenously or intramuscularly, usually for a three to five day chelation period. It increases the urinary excretion of lead through the formation of non-ionizing salts. It is crucial that the",
"    <strong>",
"     calcium",
"    </strong>",
"    disodium EDTA salt be administered, and not the disodium EDTA salt alone which binds calcium and can lead to severe hypocalcemia. Major potential toxicity with CaEDTA is kidney dysfunction. Treatment with CaEDTA should be performed in a hospital setting by clinicians experienced with chelation, in patients with normal renal function, and with careful monitoring of renal and other parameters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Provocative chelation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Provocative chelation is a mobilization test that has been proposed to give an indirect measure of lead body burden and thereby determine if chelation therapy is indicated. Some medical practices assess lead poisoning by provocative chelation with DMSA or CaEDTA, comparing urinary excretion to reference ranges for non-challenged urine specimens. Studies have failed to establish a valid correlation between prior metal exposure and post-challenge test values. The American College of Medical Toxicology (ACMT) does not support provocative chelation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Ascorbic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study found that the serum ascorbic acid level was inversely related to the blood lead level in adults and children enrolled in the NHANES III study [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/101\">",
"     101",
"    </a>",
"    ]. Animal data are supportive of a chelating effect of ascorbic acid, although human studies have so far yielded inconclusive results. However, case series and small clinical trials using ascorbic acid in doses of 100 mg to 1000 mg per day found a reduction in blood lead levels. Given the benign nature of vitamin C supplementation in modest doses (100 to 1000 mg per day), this may be an attractive adjunct to the management of patients with mild lead toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary care clinicians may find it advisable to refer patients with elevated blood lead levels, particularly above 20",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.97",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    to occupational medicine clinicians. These clinicians can not only assist in the diagnosis of lead poisoning, but can also help in arranging for environmental site evaluations and suggesting preventive measures in an effort to avoid both short-term poisoning and long-term health effects. Occupational medicine clinicians can also help with the decision for chelation therapy and then in choosing and administering the appropriate therapy. They can assist in various worker compensation and regulatory issues that arise with cases of work-related lead poisoning. Lastly, the",
"    <span class=\"nowrap\">",
"     occupational/environmental",
"    </span>",
"    medicine clinician might be able to help in setting up an appropriate lead surveillance program that is in compliance with various national and local regulations and serve to prevent lead poisoning in the future.",
"   </p>",
"   <p>",
"    Occupational medicine clinicians can be located by contacting the Association of Occupational and Environmental Clinics (AOEC), a group of occupational medicine clinics (frequently academically affiliated) with board-certified occupational medicine physicians (phone 202-347-4976; internet site:",
"    <a class=\"external\" href=\"file://www.aoec.org/\">",
"     www.aoec.org",
"    </a>",
"    ) or the American College of Occupational and Environmental Medicine Physicians (",
"    <a class=\"external\" href=\"file://www.acoem.org/\">",
"     www.acoem.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1318049\">",
"    <span class=\"h1\">",
"     PREGNANCY AND BREASTFEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In pregnant women, slight elevations in blood lead levels are of high concern because of the potential for adverse effects on the developing fetus which is more susceptible to lead's toxic effects. Even lead levels less than 10",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.48",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    may be of concern in pregnancy in light of studies demonstrating decrease in intellectual parameters on neurobehavioral testing in children with blood lead concentrations below 10",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/102\">",
"     102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11001?source=see_link&amp;anchor=H3#H3\">",
"     \"Childhood lead poisoning: Exposure and prevention\", section on 'Prenatal exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the US, routine screening of all pregnant women is not warranted given that the prevalence of blood lead levels (BLL) over 5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.24",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in pregnant women is less than 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]. However, the Centers for Disease Control and Prevention (CDC) do recommend blood lead testing for pregnant and lactating women with one or more important risk factors for lead exposure and increased BLLs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/103\">",
"     103",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recent immigration (from an area where ambient lead contamination is high)",
"     </li>",
"     <li>",
"      Living near point source of lead (eg, lead mines, smelters, battery recycling plants, home remodelling)",
"     </li>",
"     <li>",
"      Pica (ie, compulsive eating of non-food items)",
"     </li>",
"     <li>",
"      Occupational exposures (eg, painters, those exposed to batteries or radiators, living with someone who works in lead industry)",
"     </li>",
"     <li>",
"      Environmental exposures (eg, lead-contaminated soil, water, or food)",
"     </li>",
"     <li>",
"      Use of lead-containing cosmetics",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Cooking/storing",
"      </span>",
"      in lead-glazed pottery",
"     </li>",
"     <li>",
"      Use of",
"      <span class=\"nowrap\">",
"       herbal/alternative",
"      </span>",
"      medicines (eg, some Chinese herbs, Ayurvedic medicines) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=see_link&amp;anchor=H25#H25\">",
"       \"Overview of herbal medicine and dietary supplements\", section on 'Adverse effects'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If BLL during pregnancy is &lt;5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.24",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    no follow-up testing indicated. Otherwise, follow-up testing of BLLs during pregnancy depends on the initial BLL (",
"    <a class=\"graphic graphic_table graphicRef81402 \" href=\"UTD.htm?28/27/29115\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/103\">",
"     103",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Following pregnancy, lead levels can be found in breast milk (",
"    <a class=\"graphic graphic_table graphicRef87060 \" href=\"UTD.htm?23/20/23884\">",
"     table 3",
"    </a>",
"    ). CDC guidelines reinforce that breast milk is the most complete and ideal infant nourishment and advise breastfeeding as long as the mother's BLL is &lt;40",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    in countries without high infant mortality. Infants born to mothers with BLL &gt;5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    should be monitored to be sure their BLL do not rise (",
"    <a class=\"graphic graphic_table graphicRef60025 \" href=\"UTD.htm?25/14/25835\">",
"     table 4",
"    </a>",
"    ). Measurement of lead in the breast milk is not recommended.",
"   </p>",
"   <p>",
"    Providers for pregnant and lactating women with elevated BLL should ensure that the maternal lead level is known by the provider managing the newborn infant. Childhood lead poisoning, including monitoring of neonate and infant BLLs, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11001?source=see_link&amp;anchor=H3#H3\">",
"     \"Childhood lead poisoning: Exposure and prevention\", section on 'Prenatal exposure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11001?source=see_link&amp;anchor=H11089643#H11089643\">",
"     \"Childhood lead poisoning: Exposure and prevention\", section on 'Breastfeeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of lead exposure in pregnant and lactating women depends on the BLL, which is summarized in a figure (",
"    <a class=\"graphic graphic_figure graphicRef75815 \" href=\"UTD.htm?32/29/33236\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/39/12922/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/40/22146?source=see_link\">",
"       \"Patient information: Lead poisoning (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated blood lead levels have been defined for epidemiological purposes as greater than or equal to 25",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (1.21",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      in adults. However, there are also concerns about long-term exposures at blood lead levels below this level. Most lead exposure is occupational, associated with manufacturing (",
"      <a class=\"graphic graphic_table graphicRef53953 \" href=\"UTD.htm?9/3/9277\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Dimensions of the problem'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although gastrointestinal absorption is the main route of lead exposure in children, the respiratory tract is the main route in adults. Lead is a toxic metal with a relatively short half-life in blood, but a half-life of decades in the bones. It can affect many biologic systems once absorbed into the blood stream. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Biological basis for disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute clinical manifestations of lead toxicity are varied but include abdominal pain (\"lead colic\"),",
"      <span class=\"nowrap\">",
"       joint/muscle",
"      </span>",
"      aches, short-term memory problems, difficulty concentrating, irritability, anemia (sometimes accompanied by basophilic stippling on blood smear), and nephropathy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Acute exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic clinical manifestations can be non-specific and similar to acute exposure but can also include continued decline in neurocognitive function, lead nephropathy, hypertension, and increased risk of",
"      <span class=\"nowrap\">",
"       all-cause/cardiovascular",
"      </span>",
"      mortality. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Chronic exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to taking an",
"      <span class=\"nowrap\">",
"       occupational/environmental",
"      </span>",
"      history, blood lead level remains the mainstay of diagnosing lead toxicity. Bone lead concentration measured by x-ray fluorescence is a rapid, noninvasive measurement of lead in bone that is becoming increasingly standardized, although availability in most areas is limited. Individualized testing such as neurobehavioral testing can be done if indicated. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most cases of mildly elevated lead levels (&gt;20",
"      <span class=\"nowrap\">",
"       mcg/dL),",
"      </span>",
"      removal of the patient from the exposure may be the only therapy indicated. Chelation should be considered for patients with blood lead levels &gt;80",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (3.86",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      We also suggest chelation therapy for symptomatic patients with blood levels 50 to 80",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (2.42 to 3.86",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary care clinicians may find it advisable to refer patients with elevated blood lead levels, particularly above 20",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (0.97",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      to occupational medicine clinicians. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/1\">",
"      Centers for Disease Control and Prevention (CDC). Adult blood lead epidemiology and surveillance--United States, 2008-2009. MMWR Morb Mortal Wkly Rep 2011; 60:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Adult blood lead epidemiology and surveillance--United States, 2005-2007. MMWR Morb Mortal Wkly Rep 2009; 58:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/3\">",
"      Centers for Disease Control and Prevention (CDC). Blood lead levels--United States, 1999-2002. MMWR Morb Mortal Wkly Rep 2005; 54:513.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention (CDC). Fourth national report on human exposure to environmental chemicals. Atlanta:CDC 2005. Available at: file://www.cdc.gov/exposurereport/ (Accessed on July 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/5\">",
"      Kosnett MJ, Wedeen RP, Rothenberg SJ, et al. Recommendations for medical management of adult lead exposure. Environ Health Perspect 2007; 115:463.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. Occupational safety and health, Objective 20-7: Reduce the proportion of adults who have elevated blood lead concentrations. Healthy People 2010 midcourse review. Washington DC: US Department of Health and Human Services: 2007: 20-18. Available at: file://healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx?topicId=12 (Accessed on July 20, 2011).",
"    </li>",
"    <li>",
"     ATSDR. Toxicological Profile for Lead. US Department of Health &amp; Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry, Atlanta, GA 2007. Available at: file://www.atsdr.cdc.gov/toxprofiles/tp.asp?id=96&amp;tid=22 (Accessed on July 20, 2011).",
"    </li>",
"    <li>",
"     Fischbein A, Hu H. Occupational and environmental exposure to lead. In: Environmental and Occupational Medicine, Rom WN, Markowitz SB (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. p.958.",
"    </li>",
"    <li>",
"     Warren C. Brush with Death: A Social History of Lead Poisoning, The Johns Hopkins University Press, Baltimore 2000. p.32.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/10\">",
"      Centers for Disease Control (CDC). Blood-lead levels in U.S. population. MMWR Morb Mortal Wkly Rep 1982; 31:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/11\">",
"      Kaiser R, Henderson AK, Daley WR, et al. Blood lead levels of primary school children in Dhaka, Bangladesh. Environ Health Perspect 2001; 109:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/12\">",
"      Haefliger P, Mathieu-Nolf M, Lociciro S, et al. Mass lead intoxication from informal used lead-acid battery recycling in dakar, senegal. Environ Health Perspect 2009; 117:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/13\">",
"      Moszynski P. Lead poisoning in Nigeria causes \"unprecedented\" emergency. BMJ 2010; 341:c4031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/14\">",
"      Gottesfeld P, Pokhrel AK. Review: Lead exposure in battery manufacturing and recycling in developing countries and among children in nearby communities. J Occup Environ Hyg 2011; 8:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/15\">",
"      Levin SM, Goldberg M. Clinical evaluation and management of lead-exposed construction workers. Am J Ind Med 2000; 37:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/16\">",
"      Clark CS, Rampal KG, Thuppil V, et al. The lead content of currently available new residential paint in several Asian countries. Environ Res 2006; 102:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/17\">",
"      Rabito FA, Iqbal S, Perry S, et al. Environmental lead after Hurricane Katrina: implications for future populations. Environ Health Perspect 2012; 120:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/18\">",
"      Centers for Disease Control and Prevention (CDC). Potential risk for lead exposure in dental offices. MMWR Morb Mortal Wkly Rep 2001; 50:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/19\">",
"      Morgan BW, Barnes L, Parramore CS, Kaufmann RB. Elevated blood lead levels associated with the consumption of moonshine among emergency department patients in Atlanta, Georgia. Ann Emerg Med 2003; 42:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/20\">",
"      Busse F, Omidi L, Timper K, et al. Lead poisoning due to adulterated marijuana. N Engl J Med 2008; 358:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/21\">",
"      Centers for Disease Control and Prevention (CDC). Lead poisoning associated with ayurvedic medications--five states, 2000-2003. MMWR Morb Mortal Wkly Rep 2004; 53:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/22\">",
"      Saper RB, Kales SN, Paquin J, et al. Heavy metal content of ayurvedic herbal medicine products. JAMA 2004; 292:2868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/23\">",
"      Frith D, Yeung K, Thrush S, et al. Lead poisoning--a differential diagnosis for abdominal pain. Lancet 2005; 366:2146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/24\">",
"      Saper RB, Phillips RS, Sehgal A, et al. Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet. JAMA 2008; 300:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/25\">",
"      Centers for Disease Control and Prevention (CDC). Childhood lead poisoning from commercially manufactured French ceramic dinnerware--New York City, 2003. MMWR Morb Mortal Wkly Rep 2004; 53:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/26\">",
"      Centers for Disease Control and Prevention (CDC). Lead poisoning in pregnant women who used Ayurvedic medications from India--New York City, 2011-2012. MMWR Morb Mortal Wkly Rep 2012; 61:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/27\">",
"      Centers for Disease Control and Prevention (CDC). Lead poisoning associated with use of litargirio--Rhode Island, 2003. MMWR Morb Mortal Wkly Rep 2005; 54:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/28\">",
"      Centers for Disease Control and Prevention (CDC). Infant lead poisoning associated with use of tiro, an eye cosmetic from Nigeria--Boston, Massachusetts, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/29\">",
"      Buettner C, Mukamal KJ, Gardiner P, et al. Herbal supplement use and blood lead levels of United States adults. J Gen Intern Med 2009; 24:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/30\">",
"      Rabinowitz MB. Toxicokinetics of bone lead. Environ Health Perspect 1991; 91:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/31\">",
"      Hryhorczuk DO, Rabinowitz MB, Hessl SM, et al. Elimination kinetics of blood lead in workers with chronic lead intoxication. Am J Ind Med 1985; 8:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/32\">",
"      Goldman RH, White R, Kales SN, Hu H. Lead poisoning from mobilization of bone stores during thyrotoxicosis. Am J Ind Med 1994; 25:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/33\">",
"      Riess ML, Halm JK. Lead poisoning in an adult: lead mobilization by pregnancy? J Gen Intern Med 2007; 22:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/34\">",
"      Gulson BL, Mahaffey KR, Jameson CW, et al. Mobilization of lead from the skeleton during the postnatal period is larger than during pregnancy. J Lab Clin Med 1998; 131:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/35\">",
"      Valentine WN, Paglia DE, Fink K, Madokoro G. Lead poisoning: association with hemolytic anemia, basophilic stippling, erythrocyte pyrimidine 5'-nucleotidase deficiency, and intraerythrocytic accumulation of pyrimidines. J Clin Invest 1976; 58:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/36\">",
"      Struzyska L, Walski M, Gadamski R, et al. Lead-induced abnormalities in blood-brain barrier permeability in experimental chronic toxicity. Mol Chem Neuropathol 1997; 31:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/37\">",
"      Wright RO, Schwartz J, Wright RJ, et al. Biomarkers of lead exposure and DNA methylation within retrotransposons. Environ Health Perspect 2010; 118:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/38\">",
"      Wu Y, Liu Y, Ni N, et al. High lead exposure is associated with telomere length shortening in Chinese battery manufacturing plant workers. Occup Environ Med 2012; 69:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/39\">",
"      Ni Z, Hou S, Barton CH, Vaziri ND. Lead exposure raises superoxide and hydrogen peroxide in human endothelial and vascular smooth muscle cells. Kidney Int 2004; 66:2329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/40\">",
"      Wang FT, Hu H, Schwartz J, et al. Modifying effects of the HFE polymorphisms on the association between lead burden and cognitive decline. Environ Health Perspect 2007; 115:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/41\">",
"      Feldman RG. Urban lead mining: lead intoxication among deleaders. N Engl J Med 1978; 298:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/42\">",
"      Cullen MR, Robins JM, Eskenazi B. Adult inorganic lead intoxication: presentation of 31 new cases and a review of recent advances in the literature. Medicine (Baltimore) 1983; 62:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/43\">",
"      Cheson BD, Rom WN, Webber RC. Basophilic stippling of red blood cells: a nonspecific finding of multiple etiology. Am J Ind Med 1984; 5:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/44\">",
"      Thomson RM, Parry GJ. Neuropathies associated with excessive exposure to lead. Muscle Nerve 2006; 33:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/45\">",
"      Nawrot TS, Thijs L, Den Hond EM, et al. An epidemiological re-appraisal of the association between blood pressure and blood lead: a meta-analysis. J Hum Hypertens 2002; 16:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/46\">",
"      Navas-Acien A, Guallar E, Silbergeld EK, Rothenberg SJ. Lead exposure and cardiovascular disease--a systematic review. Environ Health Perspect 2007; 115:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/47\">",
"      Nash D, Magder L, Lustberg M, et al. Blood lead, blood pressure, and hypertension in perimenopausal and postmenopausal women. JAMA 2003; 289:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/48\">",
"      Hu H, Aro A, Payton M, et al. The relationship of bone and blood lead to hypertension. The Normative Aging Study. JAMA 1996; 275:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/49\">",
"      Martin D, Glass TA, Bandeen-Roche K, et al. Association of blood lead and tibia lead with blood pressure and hypertension in a community sample of older adults. Am J Epidemiol 2006; 163:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/50\">",
"      Korrick SA, Hunter DJ, Rotnitzky A, et al. Lead and hypertension in a sample of middle-aged women. Am J Public Health 1999; 89:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/51\">",
"      Khalil N, Morrow LA, Needleman H, et al. Association of cumulative lead and neurocognitive function in an occupational cohort. Neuropsychology 2009; 23:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/52\">",
"      Balbus-Kornfeld JM, Stewart W, Bolla KI, Schwartz BS. Cumulative exposure to inorganic lead and neurobehavioural test performance in adults: an epidemiological review. Occup Environ Med 1995; 52:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/53\">",
"      Weisskopf MG, Wright RO, Schwartz J, et al. Cumulative lead exposure and prospective change in cognition among elderly men: the VA Normative Aging Study. Am J Epidemiol 2004; 160:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/54\">",
"      Shih RA, Glass TA, Bandeen-Roche K, et al. Environmental lead exposure and cognitive function in community-dwelling older adults. Neurology 2006; 67:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/55\">",
"      Rajan P, Kelsey KT, Schwartz JD, et al. Lead burden and psychiatric symptoms and the modifying influence of the delta-aminolevulinic acid dehydratase (ALAD) polymorphism: the VA Normative Aging Study. Am J Epidemiol 2007; 166:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/56\">",
"      Eum KD, Korrick SA, Weuve J, et al. Relation of cumulative low-level lead exposure to depressive and phobic anxiety symptom scores in middle-age and elderly women. Environ Health Perspect 2012; 120:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/57\">",
"      Cheng Y, Schwartz J, Vokonas PS, et al. Electrocardiographic conduction disturbances in association with low-level lead exposure (the Normative Aging Study). Am J Cardiol 1998; 82:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/58\">",
"      Stewart WF, Schwartz BS, Davatzikos C, et al. Past adult lead exposure is linked to neurodegeneration measured by brain MRI. Neurology 2006; 66:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/59\">",
"      Weisskopf MG, Hu H, Sparrow D, et al. Proton magnetic resonance spectroscopic evidence of glial effects of cumulative lead exposure in the adult human hippocampus. Environ Health Perspect 2007; 115:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/60\">",
"      Shih RA, Hu H, Weisskopf MG, Schwartz BS. Cumulative lead dose and cognitive function in adults: a review of studies that measured both blood lead and bone lead. Environ Health Perspect 2007; 115:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/61\">",
"      Weisskopf MG, Weuve J, Nie H, et al. Association of cumulative lead exposure with Parkinson's disease. Environ Health Perspect 2010; 118:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/62\">",
"      Gonz&aacute;lez-Coss&iacute;o T, Peterson KE, San&iacute;n LH, et al. Decrease in birth weight in relation to maternal bone-lead burden. Pediatrics 1997; 100:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/63\">",
"      Bellinger D, Leviton A, Waternaux C, et al. Longitudinal analyses of prenatal and postnatal lead exposure and early cognitive development. N Engl J Med 1987; 316:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/64\">",
"      Gomaa A, Hu H, Bellinger D, et al. Maternal bone lead as an independent risk factor for fetal neurotoxicity: a prospective study. Pediatrics 2002; 110:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/65\">",
"      Rothenberg SJ, Kondrashov V, Manalo M, et al. Increases in hypertension and blood pressure during pregnancy with increased bone lead levels. Am J Epidemiol 2002; 156:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/66\">",
"      Hu H, T&eacute;llez-Rojo MM, Bellinger D, et al. Fetal lead exposure at each stage of pregnancy as a predictor of infant mental development. Environ Health Perspect 2006; 114:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/67\">",
"      Lancranjan I, Popescu HI, GAvnescu O, et al. Reproductive ability of workmen occupationally exposed to lead. Arch Environ Health 1975; 30:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/68\">",
"      Alexander BH, Checkoway H, van Netten C, et al. Semen quality of men employed at a lead smelter. Occup Environ Med 1996; 53:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/69\">",
"      Robins TG, Bornman MS, Ehrlich RI, et al. Semen quality and fertility of men employed in a South African lead acid battery plant. Am J Ind Med 1997; 32:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/70\">",
"      Ng TP, Goh HH, Ng YL, et al. Male endocrine functions in workers with moderate exposure to lead. Br J Ind Med 1991; 48:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/71\">",
"      Lustberg M, Silbergeld E. Blood lead levels and mortality. Arch Intern Med 2002; 162:2443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/72\">",
"      Menke A, Muntner P, Batuman V, et al. Blood lead below 0.48 micromol/L (10 microg/dL) and mortality among US adults. Circulation 2006; 114:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/73\">",
"      Schober SE, Mirel LB, Graubard BI, et al. Blood lead levels and death from all causes, cardiovascular disease, and cancer: results from the NHANES III mortality study. Environ Health Perspect 2006; 114:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/74\">",
"      Weisskopf MG, Jain N, Nie H, et al. A prospective study of bone lead concentration and death from all causes, cardiovascular diseases, and cancer in the Department of Veterans Affairs Normative Aging Study. Circulation 2009; 120:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/75\">",
"      Schaumberg DA, Mendes F, Balaram M, et al. Accumulated lead exposure and risk of age-related cataract in men. JAMA 2004; 292:2750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/76\">",
"      Park SK, Elmarsafawy S, Mukherjee B, et al. Cumulative lead exposure and age-related hearing loss: the VA Normative Aging Study. Hear Res 2010; 269:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/77\">",
"      Arora M, Weuve J, Weisskopf MG, et al. Cumulative lead exposure and tooth loss in men: the normative aging study. Environ Health Perspect 2009; 117:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/78\">",
"      Krishnan E, Lingala B, Bhalla V. Low-level lead exposure and the prevalence of gout: an observational study. Ann Intern Med 2012; 157:233.",
"     </a>",
"    </li>",
"    <li>",
"     National Toxicology Program, US Dept of Health and Human Services. 12th Report on Carcinogens, 2011. Lead and Lead Compounds(CAS No. 7439-92-1 (Lead)). Available at: file://ntp.niehs.nih.gov/ntp/roc/twelfth/profiles/Lead.pdf (Accessed on July 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/80\">",
"      White RF, Diamond R, Proctor S, et al. Residual cognitive deficits 50 years after lead poisoning during childhood. Br J Ind Med 1993; 50:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/81\">",
"      Hu H. A 50-year follow-up of childhood plumbism. Hypertension, renal function, and hemoglobin levels among survivors. Am J Dis Child 1991; 145:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/82\">",
"      Hu H. Knowledge of diagnosis and reproductive history among survivors of childhood plumbism. Am J Public Health 1991; 81:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/83\">",
"      US Department of. Occupational exposure to lead. Fed Reg 1978; :43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/84\">",
"      U.S. Department of Labor, Occupational Safety and Health Administration. 29 CFR Part 1926: Lead exposure in construction; interim final rule. Fed Reg 1993; :58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/85\">",
"      Taylor L, Jones RL, Ashley K, et al. Comparison of capillary earlobe and venous blood monitoring for occupational lead surveillance. J Lab Clin Med 2004; 143:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/86\">",
"      Hu H, Rabinowitz M, Smith D. Bone lead as a biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms. Environ Health Perspect 1998; 106:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/87\">",
"      Hu H, Shih R, Rothenberg S, Schwartz BS. The epidemiology of lead toxicity in adults: measuring dose and consideration of other methodologic issues. Environ Health Perspect 2007; 115:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/88\">",
"      Hu H. Bone lead as a new biologic marker of lead dose: recent findings and implications for public health. Environ Health Perspect 1998; 106 Suppl 4:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/89\">",
"      Barbosa F Jr, Tanus-Santos JE, Gerlach RF, Parsons PJ. A critical review of biomarkers used for monitoring human exposure to lead: advantages, limitations, and future needs. Environ Health Perspect 2005; 113:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/90\">",
"      Park SK, Mukherjee B, Xia X, et al. Bone lead level prediction models and their application to examine the relationship of lead exposure and hypertension in the Third National Health and Nutrition Examination Survey. J Occup Environ Med 2009; 51:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/91\">",
"      Chia SE, Chia HP, Ong CN, Jeyaratnam J. Cumulative blood lead levels and neurobehavioral test performance. Neurotoxicology 1997; 18:793.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Occupational and Environmental Medicine. Recommendation to OSHA Regarding Blood Lead Levels. 2010. Available at: file://www.acoem.org/BloodLeadLevels.aspx (Accessed on October 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/93\">",
"      Centers for Disease Control and Prevention (CDC). Adult blood lead epidemiology and surveillance--United States, 2003-2004. MMWR Morb Mortal Wkly Rep 2006; 55:876.",
"     </a>",
"    </li>",
"    <li>",
"     Association for Occupational and Environmental Clinics: Medical management guidelines for lead exposed adults. Available at: www.aoec.org/documents/positions/MMG_FINAL.pdf (Accessed on July 20, 2011).",
"    </li>",
"    <li>",
"     Kosnett MJ. Lead. In: Critical Care Toxicology: Diagnosis and Management of the Critically Poisoned Patient, Brent J, Phillips SD, Wallace KL, et al.  (Eds), Elsevier Mosby, 2005. p.821.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/96\">",
"      Grandjean P, Jacobsen IA, J&oslash;rgensen PJ. Chronic lead poisoning treated with dimercaptosuccinic acid. Pharmacol Toxicol 1991; 68:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/97\">",
"      Lin JL, Ho HH, Yu CC. Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency. A randomized, controlled trial. Ann Intern Med 1999; 130:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/98\">",
"      Porru S, Alessio L. The use of chelating agents in occupational lead poisoning. Occup Med (Lond) 1996; 46:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/99\">",
"      Bradberry S, Sheehan T, Vale A. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. QJM 2009; 102:721.",
"     </a>",
"    </li>",
"    <li>",
"     Charlton N, Wallace KL. American College of Medical Toxicology Position Statement on post-chelator challenge urinary metal testing. Available at: file://acmt.net/cgi/page.cgi?aid=2999&amp;_id=52 (Accessed on July 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/101\">",
"      Simon JA, Hudes ES. Relationship of ascorbic acid to blood lead levels. JAMA 1999; 281:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/102\">",
"      Canfield RL, Henderson CR Jr, Cory-Slechta DA, et al. Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. N Engl J Med 2003; 348:1517.",
"     </a>",
"    </li>",
"    <li>",
"     Ettinger, AS, Gurthrie Wengrovitz, A (Eds). Guidelines for the identification and management of lead exposure in pregnant and lactating women. National Center for Environmental Health/Agency for Toxic Substances and Disease Registry; Centers for Disease Control and Prevention, Atlanta, GA, 2010  available at file://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/39/12922/abstract/104\">",
"      Rischitelli G, Nygren P, Bougatsos C. Screening for elevated lead levels in childhood and pregnancy: Update of a 1996 United States Preventive Services Task Force review. U.S. Preventive Services Task Force Evidence Syntheses.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2773 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-EFEE8658EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_39_12922=[""].join("\n");
var outline_f12_39_12922=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIMENSIONS OF THE PROBLEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sources of exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BIOLOGICAL BASIS FOR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Acute exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chronic exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Neuropsychiatric effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Reproductive effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Site of blood sampling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Reducing lead exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Chelation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - DMSA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Calcium EDTA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Provocative chelation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Ascorbic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1318049\">",
"      PREGNANCY AND BREASTFEEDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2773\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2773|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?27/26/28067\" title=\"algorithm 1\">",
"      Occupation environment history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2773|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/52/25422\" title=\"figure 1\">",
"      Leaded gasoline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/6/42081\" title=\"figure 2\">",
"      Lead induced side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/29/33236\" title=\"figure 3\">",
"      Summary of public health actions based on blood lead levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2773|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/33/24095\" title=\"picture 1\">",
"      Lead line in gingival tooth border",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/22/40294\" title=\"picture 2\">",
"      Basophilic stippling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2773|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/3/9277\" title=\"table 1\">",
"      Sources of lead exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/27/29115\" title=\"table 2\">",
"      Frequency of maternal blood lead follow-up testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/20/23884\" title=\"table 3\">",
"      Key considerations for breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/14/25835\" title=\"table 4\">",
"      Maternal blood lead follow-up testing during lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=related_link\">",
"      Childhood lead poisoning: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11001?source=related_link\">",
"      Childhood lead poisoning: Exposure and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6138?source=related_link\">",
"      Clinical aspects, diagnosis, and treatment of the sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5705?source=related_link\">",
"      Lead nephropathy and lead-related nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=related_link\">",
"      Overview of herbal medicine and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14553?source=related_link\">",
"      Overview of occupational and environmental health",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/40/22146?source=related_link\">",
"      Patient information: Lead poisoning (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_39_12923="Abnormal red cell ion transport";
var content_f12_39_12923=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F80358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F80358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hematologic diseases characterized by abnormal red cell ion transport",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Transport abnormality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sickle cell syndromes",
"       </td>",
"       <td>",
"        Cellular dehydration mediated by increases in K-Cl cotransport and activity of the calcium-activated (Gardos) potassium channel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beta thalassemia",
"       </td>",
"       <td>",
"        Relative cellular dehydration mediated by K-Cl cotransport",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin C disease",
"       </td>",
"       <td>",
"        Cellular dehydration mediated by increased K-Cl cotransport",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hereditary spherocytosis",
"       </td>",
"       <td>",
"        Increased sodium and potassium permeability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hereditary stomatocytosis",
"       </td>",
"       <td>",
"        Hyperhydration due to increased sodium permeability or dehydration (xerocytosis) associated with enhanced potassium loss",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_39_12923=[""].join("\n");
var outline_f12_39_12923=null;
var title_f12_39_12924="Nonverbal skills pt interview";
var content_f12_39_12924=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nonverbal skills applying to all functions of medical interview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Strategy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rationale",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Professional appearance",
"       </td>",
"       <td>",
"        Conveys confidence and expertise",
"       </td>",
"       <td>",
"        Well-kempt; with or without white coat, depending on expectations of majority of patient population",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Comfortable office",
"       </td>",
"       <td>",
"        Helps patient and clinician relax, conveys professionalism, and can convey sense of clinician's level of organization and aesthetic taste",
"       </td>",
"       <td>",
"        Appropriate temperature; no barriers to direct eye contact; gowns that fit; efficient organization of exam room; attention to modesty; minimization of interruptions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calm, attentive, open posture",
"       </td>",
"       <td>",
"        Conveys readiness to listen",
"       </td>",
"       <td>",
"        Comfortable interpersonal distance; patient and clinician at eye level (consider implications of vertical distance on patient's comfort); clinician leans slightly forward, relaxed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eye contact",
"       </td>",
"       <td>",
"        Conveys focused interest on the patient; clinician is not distracted",
"       </td>",
"       <td>",
"        Clinician looks patient directly in the eye while talking and listening; consider the effect of note-taking style on the flow of the interview",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voice quality: pitch, pace, tone, volume (paralanguage)",
"       </td>",
"       <td>",
"        Conveys much about clinician's tranquillity and readiness to hear patient; respectful of hearing deficits",
"       </td>",
"       <td>",
"        Calm versus brusque and hurried; loud/soft enough; avoid hostile, scolding, or irritated quality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clinician \"matches\" some of the patient's behaviors",
"       </td>",
"       <td>",
"        Subliminal enhancement of relationship",
"       </td>",
"       <td>",
"        Clinician's posture echoes patient's posture; clinician's voice tone, pace, and vocabulary matches patient's; clinician's gestures subtly echo patient's",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Doctors should be aware that many nonverbal behaviors have special cross-cultural implications.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted by permission from Clark W, Hewson M, Fry M, et al. American Academy on Physician and Patient (AAPP) 1998.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_39_12924=[""].join("\n");
var outline_f12_39_12924=null;
var title_f12_39_12925="Ewing tumor immunohistochemistry";
var content_f12_39_12925=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Immunohistochemical staining in the differential diagnosis of Ewing sarcoma family of tumors and other small round blue cell tumors of childhood",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Marker",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Ewing's",
"sarcoma",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        PNET",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Neuro-blastoma",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Rhabdomyo-sarcoma",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Lymphoma*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Typical",
"       </td>",
"       <td class=\"subtitle2\">",
"        Atypical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NSE",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S-100",
"       </td>",
"       <td>",
"        _",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NFTP",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -/+",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Desmin",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -/+",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Actin",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vimentin",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytokeratin",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LCA",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -/+",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HNK-1",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &beta;2-microglobulin",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HBA71",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +&Delta;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PNET: primitive neuroectodermal tumor; -: negative; +/-: positive in greater than 10 percent of cases; -/+: positive in less than 10 percent of cases; +: positive; NSE: neuron specific enolase; LCA: leucocyte common antigen.",
"     <br>",
"      * Nonhistiocytic.",
"      <br>",
"       &bull; Only in ganglion cells, Schwann cells, and stage IVS.",
"       <br>",
"        &Delta; Only well-differentiated rhabdomyoblasts.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ginsberg JP, Woo SY, Johnson ME, et al. Ewing's sarcoma familiy of tumors: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. In: Principles and Practice of Pediatric Oncology, 4th ed, Pizzo PA, Poplack DG (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_39_12925=[""].join("\n");
var outline_f12_39_12925=null;
var title_f12_39_12926="Energy intake nitrogen balance";
var content_f12_39_12926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F77072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F77072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Relation between energy intake and nitrogen balance in chronic renal failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 269px; height: 257px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A direct correlation between energy intake (kcal/kg desirable body weight per day) and nitrogen balance in six hemodialysis patients after reaching equilibration on three different diets. Providing a relatively low level of 25 kcal/kg per day led to weight loss and negative nitrogen balance. In comparison, positive nitrogen balance was induced in all of the patients on the highest energy intake. The P values are versus the values for an energy intake of 25 kcal/kg per day.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Slomowitz, LA, Monteon, FJ, Grosvenor, M, et al, Kidney Int 1989; 35:704.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_39_12926=[""].join("\n");
var outline_f12_39_12926=null;
var title_f12_39_12927="Nociceptor sensitization following tissue injury";
var content_f12_39_12927=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Nociceptor sensitization following tissue injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 295px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nociceptor sensitization is partly mediated by the release of toxic substances (potassium, prostaglandin, bradykinins, and substance P) from damaged tissue. Those toxic substances excite nociceptors and increase their sensitivity to pain (hyperalgesia). Substance P, released by an axon reflex, induces vasodilation and mast-cell degranulation leading to histamine and serotonin release. These inflammatory agents sensitize damaged tissue and surrounding nociceptors even further prolonging the hypersensitivity state (secondary hyperalgesia).",
"    <div class=\"footnotes\">",
"     K+: potassium; PG: prostaglandin; BK: bradykinin; SP: substance P; 5HT: serotonin.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Sosnowski M, Lebrun P, Fodderie L, Anesth Clin North Am 1992; 10:211.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_39_12927=[""].join("\n");
var outline_f12_39_12927=null;
